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A B S T R A C T
Poorly water-soluble drugs continue to be a problematic, yet important class of pharmaceutical compounds for
treatment of a wide range of diseases. Their prevalence in discovery is still high, and their development is usually
limited by our lack of a complete understanding of how the complex chemical, physiological and biochemical
processes that occur between administration and absorption individually and together impact on bioavailability.
This review defines the challenge presented by these drugs, outlines contemporary strategies to solve this
challenge, and consequent in silico and in vitro evaluation of the delivery technologies for poorly water-soluble
drugs. The next steps and unmet needs are proposed to present a roadmap for future studies for the field to
consider enabling progress in delivery of poorly water-soluble compounds.
1. Introduction
Poorly water-soluble drugs present ongoing challenges with their
translation into viable medicinal products. The hurdles to their suc-
cessful oral delivery are a complex web of physical-chemical, biolo-
gical, physiological and anatomical factors that act independently and
in concert to limit drug bioavailability. The actions of the mechanical
and environmental conditions on the initial dose form is reasonably
well characterized – disintegration or rupture of dose forms is rather
well understood principally from imaging and other studies (Hens et al.,
2017a). However, it is the processing of drug after it is unveiled from
the dosage form that is incompletely understood. The solid-state
characteristics of the drug and transformations between different states
in the gastrointestinal environment are not easily assessed in complex
dynamic environments. The more recent trends toward amorphous high
energy forms of drug presents a problem of unpredictable crystal-
lization with consequences for solubilization and bioavailability. The
tendency toward crystallization can be anticipated, however the com-
plex media of the gastrointestinal tract installs a level of uncertainty
around this. The response of excipients to the complex digestive en-
vironment of the gut through changes in solubility, degradation by li-
pases, proteases and other enzymes is individual-dependent, and the
consequent interaction of dissolving drug with those components is not
yet completely predictable. The gut also responds specifically and
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individually to the nature of the excipients, further complicating the
gastric phase of delivery (Ladas et al., 1984). In the case of lipid for-
mulations, drug precipitation on dilution and digestion is an ever-pre-
sent risk. Digestion of the lipids in the formulation by lipases induces
self-assembled colloid formation, and we do not yet know the cascade
of structures and specific interactions with poorly soluble drugs that can
help or hinder bioavailability as a consequence. Even when the drug is
completely dissolved in the remnants of the formulation and ready for
absorption, biochemical and post absorption factors usually conspire to
further limit bioavailability but may in some cases help by promoting
e.g. lymphatic transport (Porter et al., 2007).
In consideration of this multi-facetted problem, there is a need to
approach this problem from an interdisciplinary standpoint. For dec-
ades, pieces of this puzzle have been tackled somewhat in isolation by
research groups – while great advances have been made in specific
areas, there is no globally unifying approach to bring these findings
together to present ways to tackle such problematic drugs in a holistic
manner. We may never get there, but by bringing together multi-
disciplinary clusters to work at the interfaces between groups, we
provide the best opportunity of learning how to address these multiple
barriers through new delivery technologies, diagnostic approaches and
analytical advances.
With this principle in mind, the recently formed European Network
on Understanding Gastrointestinal Absorption-related Processes
(UNGAP), funded under COST action CA16205, are aiming to advance
the field of intestinal drug absorption through a multidisciplinary in-
ternationally collaborative approach. Two of the four major challenges
they have defined relate to poorly water-soluble drugs, namely the in-
traluminal behavior of advanced formulations (usually required for the
effective delivery of poorly water-soluble drugs), and the food-drug
interface, which is crucial in consideration of the often lipophilic nature
of such compounds.
The purpose therefore of this review is to share the current state of
knowledge around the issues, approaches and requirements for future
developments in the field as seen by this multidisciplinary team. For the
team, this enables definition of both a foundation and roadmap to
impact across these challenges, a large initial part being to share a
common language, terminology and understanding of needs in the field.
For the general reader, this review collates current thinking from this
diverse group of researchers, united in the goal to advance the delivery
field around poorly water-soluble drugs. The review defines the chal-
lenge presented by these drugs, outlines contemporary strategies to
solve this challenge, consequent compendial and biorelevant in vitro
evaluation of the delivery technologies in order to limit the usage of
animals, before moving onto defining the unmet needs and future di-
rections for the field and for UNGAP to address. The need for con-
sideration of new paradigms is timely with developments in not only
materials for drug delivery, but also in new imaging and analytical
techniques and facilities that if embraced and addressed by such a
multidisciplinary approach can lead to significant gains in overcoming
the limitations to formulation and delivery of problematic compounds.
2. Challenging molecules after oral administration and common
formulation strategies to overcome these unfavorable compounds
characteristics
A large fraction of contemporary drug compounds has physico-
chemical properties that may result in low chemical stability in the
gastrointestinal (GI) tract, poor and/or variable solubility in the fasted
and fed state gastrointestinal fluids and eventually poor permeation
across the intestinal wall. Most of the small molecules display poor
aqueous solubility and it is not uncommon that lead compounds se-
lected during the discovery stage show solubility in the lower μg/mL
region. This fact has been attributed to the chemical approaches used,
the organizational factor and last but not least, the lipophilic molecular
requirements of contemporary targets (Bergström et al., 2016; Keserü
and Makara, 2009; Leeson and Springthorpe, 2007; Leeson and St-
Gallay, 2011; Vieth and Sutherland, 2006). Indeed, many targets cur-
rently under exploration have highly lipophilic endogenous ligands,
which is translated to the need for certain lipophilicity in the mod-
ulating drug. The impact of molecular properties on solubility, and the
role of the fasted and fed state on the resulting solubility, has been
explored by different computational tools; the relation between physi-
cochemical properties and solubility is further discussed in Section 2.1.
Taken together, poor solubility and permeability are significantly lim-
iting the absorption of contemporary drugs after oral delivery. In the
next section, the relationship between molecular properties and solu-
bility/permeability will be described.
2.1. Physicochemical considerations
Yalkowsky and coworkers established the General Solubility
Equation (GSE) in 2001. This identifies the strong link between the
solid state and the lipophilicity of the compound, and the resulting
aqueous solubility (Jain and Yalkowsky, 2001):=log S T logP0.5 0.01( 25)m0 (1)
where S0 is the intrinsic solubility, i.e. the solubility of the non-ionized
(neutral) species, Tm is the melting point (°C) and logP is the partition
coefficient between octanol and water. Wassvik et al. used the GSE and
hypothetical values for melting point (Tm of 50, 150 and 250 °C) and
the lipophilicity (logP of 2, 4 and 6) to separate compounds that are
mainly limited by the solid state, from those limited by their poor
solvation (Wassvik et al., 2008). Compounds with a strong crystal lat-
tice often show a limited capacity to dissociate from the solid form and
these are commonly referred to as ‘brick dust’ molecules. In a similar
way, a logP cut-off of 3 has been put forward as an indicator of sig-
nificantly reduced interaction with aqueous solvents (Bergström et al.,
2016). Compounds with a logP>3 are commonly referred to as ‘grease
ball’ molecules. It should be noted that, for ionizable compounds, it is
the corresponding logD value (at the pH of interest) that should be
greater than the logP cut-off value (Fagerberg and Bergström, 2015). In
addition to these, there are compounds that display both high logP and
high melting point, i.e. they are both solid state and solvation limited in
the solubility. Computational modelling of several dataset has linked
molecular properties to solid-state- versus solvation-limited solubility
(Bergström et al., 2007; Fagerberg et al., 2010; Wassvik et al., 2008;
Zaki et al., 2010). Solvation-limited compounds are lipophilic, rela-
tively large molecules, and lack conjugated systems. In contrast,
common features for solid-state-limited compounds are flatness, ex-
tended ring structures and high aromaticity. In addition to modelling of
solubility in pure water or simple buffers, models to identify solubility
in more complex solvents such as intestinal fluids have been developed
(Fagerberg et al., 2015). In these studies, size and aromaticity were
negatively linked to the solubility, whereas the hydrogen bond capacity
(donors and acceptors) was a positive factor for solubility.
It is well-known that lipophilicity is positively linked to permeation.
However, there is also a trade-off when it comes to lipophilicity; too
lipophilic compounds may strongly favor the lipid-rich environment to
an extent at which its permeation across the lipid bilayer becomes
limited. Negatively linked properties to permeation are size and po-
larity, the latter typically being described as polar surface area, or hy-
drogen bond donors and acceptors (Palm et al., 1997; Veber et al.,
2002). The polarity limitation significantly reduces the permeation of
small, hydrophilic molecules and these eventually make use of different
active transporters or they permeate the intestinal wall via the para-
cellular route. To further improve the permeability of such compounds,
chemical modifications may be used to change the physicochemical
properties. A common strategy to apply is to develop prodrugs which
either block polar groups and increase the lipophilicity of the molecule,
and hence increase the transcellular passive diffusion across the en-
terocytes or couple a handle ‘visible’ to active transporters (Murakami,
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2016; Wang et al., 1999). From a formulation perspective, permeability
enhancers may be added to increase the flux through the paracellular
route (Anderberg et al., 1993; Lindmark et al., 1995). This is especially
relevant for macromolecules, where the size and polarity result in a
limited permeation. Also, for such compounds chemical modifications
can be used to increase the membrane permeability with the main focus
being to reduce the polarity. One successful strategy is to design mo-
lecules with capacity to form intramolecular hydrogen bonds. This
enables the compound to display the hydrogen bond donors and ac-
ceptors to the water phase in the intestine and thereby increasing the
water solubility, whereas the molecule shields these functions from the
lipid bilayer through internal bond formation when it encounters the
lipid environment and thereby increases the permeation through the
cellular membrane (Rossi Sebastiano et al., 2018).
2.2. Solubility and dissolution rate enhancement
Insufficient aqueous solubility compared to the dose that needs to
be administered (dose number D0 > 1, Biopharmaceutic Classification
System (BCS)) is one of the most frequently encountered problems for
drug substance formulation. The low equilibrium solubility leads to
very slow drug dissolution rate and poor intestinal absorption. The
current formulation strategies to overcome these issues can be sepa-
rated in two major categories: (1) methods that increase the apparent
equilibrium drug solubility and the dissolution rate, and (2) techniques
that increase the dissolution rate and facilitate the formation of meta-
stable supersaturated drug solutions. Of course, sophisticated techni-
ques that combine the properties of (1) and (2) also exist (e.g.
salts+ precipitation inhibitors, some lipid-based formulations). An
important aspect of solubility is the distinction between apparent drug
solubility (e.g. drug solubilized in micelles, liposomes, cyclodextrins
etc.) and molecularly soluble “free” drug (i.e. in supersaturated solu-
tions). The implications of the latter on drug permeability and ab-
sorption are discussed in detail in Section 5.4.
In the next paragraphs, the main concept, application scope, ad-
vantages and limitations of the techniques that are widely used to en-
hance drug solubility in the context of oral delivery (pharmaceutical
salts) or are emerging as enabling technologies (amorphous solid dis-
persions, lipid-based formulations) will be shortly described, including
example cases where appropriate. The drug solubilization by surfac-
tants will also be briefly outlined, due to the wide spread use of this
family of excipients in both standard and advanced formulations.
Approaches with limited application in the context of oral delivery (e.g.
co-solvents, polymeric micelles, liposomes), or which have been re-
cently reviewed (cyclodextrins (Adeoye and Cabral-Marques, 2017) will
be omitted from the current discussion). Although particle size reduc-
tion techniques increase the dissolution rate, their effect is limited for
drugs with very poor equilibrium solubility in water. Hence, they find
application only in combination with other solubility enhancement
approaches and will not be described separately. The lipid-based drug
delivery systems and their central role as enabling formulations for the
oral route are presented at the end of the section. The presented tech-
nologies may be used as (pre)clinical formulations or intermediate oral
products. These are clearly emerging systems for oral delivery of poorly
water-soluble drugs.
2.2.1. Salt formation
The solubility and dissolution rate of ionizable drugs can be im-
proved significantly by preparing their respective salts. Due to the
simplicity and cost-efficiency of the concept, it has been extensively
used both for oral and parenteral delivery (Paulekuhn et al., 2007). The
major advantage of the method is that it can provide considerable in-
crease of solubility (often by>3 orders of magnitude (Elder et al.,
2013)) and dissolution rate without the need to chemically modify the
drug molecule or to use complex enabling formulations.
In order to have a complete proton transfer and, hence, obtain a salt,
a difference of 2–3 units between the pKa of the counterion and the pKa
of the drug is required (Berry and Steed, 2017). Drug molecules with
more than one ionization moiety display more complex behavior, due
to the polyprotic and polybasic equilibria (Maurin et al., 2002). In this
case, whether the mono- or poly-salts are preferred for development has
to be decided depending on their solubility properties, stability, scal-
ability etc.
The solubility of the salt can depend significantly on the type of
counterion and should be directly linked to parameters such as the
crystal lattice free energy and the hydration free energies of the ions
(Anderson and Flora, 1996). However, there are still no approaches that
allow its accurate prediction. For example, the type of structurally si-
milar organic acids (tartaric, succinic, lactic, acetic) had no significant
effect on the solubility of the weak base avitriptan (Serajuddin, 2002),
whereas for diclofenac the addition of one OH-group to the tert-buty-
lamine counterion increased the salt solubility 4-fold (O'Connor and
Corrigan, 2001). Furthermore, using a tertiary amine (2-dimethylami-
noethanol) as a diclofenac salt forming agent resulted in a> 80-fold
increase of the salt solubility, compared to the tert-butylamine salt.
Another important parameter of a salt that has to be considered,
especially in the context of oral delivery, is the pHmax: the pH value at
which the maximum solubility of the drug is obtained. This parameter
is critical, as it governs the conversion of the ionized form to its con-
jugate free base or free acid and, hence, the precipitation behavior in
the gastrointestinal tract. The higher the pHmax of a basic drug (or the
lower, for an acidic drug), the easier the formation of a salt is, and the
better its stability to conversion to the non-ionized form. The magni-
tude of the pHmax for a basic drug can be assessed by Bogardus and
Blackwood (1979):
= +pH pK S
K
loga
sp
max
0
(2)
where pKa is the ionization constant of the drug, S0 is the intrinsic so-
lubility of the non-ionized form of the drug and Ksp is the solubility
product of the salt. Therefore, for a basic drug, the pHmax increases with
the increase of the strength of the base (higher pKa), with the increase of
the solubility of the base (S0) and with the decrease in salt solubility
(Ksp). A similar equation, which shows that for an acidic drug pHmax
decreases with the increase of S0 and with the decrease of pKa and Ksp
can also be written.
The solubility product of the salt is important not only because it
characterizes its solubility and influences the pHmax, but also in relation
to the common ion effect that can dramatically reduce salt solubility in
biorelevant conditions. In particular, the solubility of hydrochloride
salts of basic drugs can be significantly decreased in the stomach, due to
the high concentration chloride anions via the following equation:
=S K
Cion
sp
CI (3)
where the Sion is the solubility of the drug in its ionized form and CCI is
the counterion concentration. The latter leads to the counterintuitive
effect of decreased solubility when the pH is significantly lower than
the pHmax for basic drugs. Note that the common ion effect in stomach
conditions should be considered not only when hydrochloric acid is
used for salt preparation, but also when weaker acids (e.g. organic) are
used, as these salts could be transformed to the respective hydro-
chloride salt in situ in the stomach. A pronounced effect can also be
expected when the solubility of the salt is in the low-millimolar range,
i.e. for drugs with extremely poor water solubility and low solubility
enhancement.
A major issue with the application of salts in oral delivery is their
behavior in biorelevant conditions. If the pHmax is not in the range of
physiological pH values, precipitation can occur. This is usually the case
for acidic drugs in the stomach and basic drugs in the intestine.
However, the quick redissolution of the precipitate (phase-separated
drug) normally facilitates significantly higher oral absorption,
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compared to the non-ionized form. The mechanisms that account for
the quick redissolution include high surface are of the precipitate (e.g.
Phenytoin sodium (Dill et al., 1956; Serajuddin and Jarowski, 1993))
and formation of non-equilibrium metastable states with high thermo-
dynamic activity (e.g. emulsion of supercooled melt droplets of diclo-
fenac sodium (Stahl and Nakano, 2002) or amorphous gel formation
(Serajuddin, 2007)).
During the selection of a pharmaceutical salt for development, a
number of additional factors such as solid-state properties (Raumer
et al., 2006), stability (Nie et al., 2017; Stephenson et al., 2011) and
toxicity (Stahl and Wermuth, 2008) should also be considered in detail.
The solubility of the salt and pHmax are not always the main determi-
nants in selection, as scalability and stability during processing (e.g.
deliquescence, amorphization, disproportionation) might prevent
manufacturing of the salt and could warrant the selection of a salt with
lower solubility, but better stability, or the use of the non-ionized form
(Korn and Balbach, 2014).
There are several limitations of the pharmaceutical salts approach,
the most important being the requirement for ionizable groups in the
drug molecule. The latter can be circumvented in some degree by using
the co-crystallization approach, as highlighted by several recent re-
views (Elder et al., 2013; Kuminek et al., 2016). Cocrystallization takes
advantage of intermolecular interactions (usually of hydrogen bond-
type) between the poorly soluble drug and a hydrophilic coformer to
produce cocrystals with significantly enhanced drug solubility. Guide-
lines for cocrystal synthesis and the importance of cocrystal eutectic
constants as a tool for prediction of cocrystal behavior in different
media (pH, surfactants) are described in the comprehensive review by
Kuminek et al. (2016).
Another limitation is that the degree of solubility enhancement
might not be sufficient for drugs with extremely poor aqueous solubility
(e.g. itraconazole), and that the common ion effect would be very
pronounced. In these cases, ionic liquids could be prepared (Agatemor
et al., 2018): these are low-melting point (Tm < 100 °C) salts that
consist of a drug+ bulky counterion. They could either be used for oral
delivery by themselves (Shamshina et al., 2013), or if the counterion is
hydrophobic, the resulting hydrophobic ionic liquid could be combined
with lipid-based formulations (Williams et al., 2014a) that will be de-
scribed later in the section.
Another option is to combine the salt concept with other solubility
enhancement approaches, such as the amorphous solid disper-
sions+ precipitation inhibitors, which will be described in the fol-
lowing paragraphs.
2.2.2. Amorphous solid dispersions
One of the modern approaches that provides both dramatic increase
in drug dissolution rate and suitable supersaturation conditions is to
modify the solid-state properties of the drug. Ideal amorphous solid
dispersions (ASD) can be defined as glass solutions of a poorly soluble
drug in an amorphous carrier that represent a single-phase amorphous
system (van den Mooter, 2012).
The ease of preparation of a drug in amorphous from can be
straightforward (good glass formers) or difficult (poor glass formers)
(Yu, 2001). In general, molecules that are difficult to arrange in a
crystal lattice, have high conformational flexibility and/or have con-
figurational isomers, tend to have small difference in the free energy of
the crystal state, compared to the amorphous state and thus are good
glass formers. The classical amorphization techniques could be broadly
separated in three main categories: (1) mechanical energy input
methods, (2) solvent methods and (3) melt methods. The first category
includes different type of mills (e.g. oscillatory ball milling, fluid energy
mill) (Descamps and Willart, 2016) and wet granulation. The second
group consists of anti-solvent techniques, lyophilization and spray-
drying (Singh and Van den Mooter, 2016). The third group includes
melt agglomeration (the drug melt is used as a granulation liquid) and
hot-melt extrusion (the drug is melted or/and dissolved in a polymer
melt, which is then cooled down and extruded (Sarode et al., 2013)).
Each family of techniques has certain advantages and pitfalls. The
common milling methods are simple and do not require complex ma-
chinery but have lower amorphization efficiency and are less robust. On
the other hand, the solvent and melt methods have good scalability and
are used in the manufacturing of ASD. Solvent methods allow the for-
mation of ASD at low temperatures, but then face difficulties in elim-
inating traces of solvent (often toxic) from the final product. On the
other hand, melt methods do not have problems with toxicity (if the
polymer and/or other excipients are biocompatible), but cannot be used
for thermally unstable compounds and the selection of a polymer with
high molecular drug solubility is still a challenge. For more detailed
description of the ASD manufacturing methods the reader is referred to
a recent review article (Vasconcelos et al., 2016).
A major issue in ASD formulations is their innate thermodynamic
instability, related to the transition of the amorphous solid to its stable
crystal form. One of the key parameters in this context is the glass
transition temperature (Tg), which is defined as the critical temperature
below which a glassy solid is obtained. Higher Tg is associated with
better physical stability during storage and processing. An additional
layer of complexity is that the transition of an amorphous solid to
crystalline state can pass through a number of crystalline mesophases
(Shalaev et al., 2016) with intermediate properties. Therefore, the
solid-state properties of the amorphous material during in vitro dis-
solution and in vivo experiments, as well as during processing and
storage, has to be monitored if mechanistic interpretation of the data is
desired. However, the complex character of the different relaxation
processes in amorphous systems (time scale span of> 10 orders of
magnitude (Hancock and Shamblin, 2001)) has posed a significant
challenge. The analytical techniques which allow one to assess the
molecular mobility and thus judge the solid state of the drug include
calorimetric, spectroscopic and scattering methods. In recent years,
significant progress has been made in the use of Raman (Hédoux, 2016)
and terahertz spectroscopy (Sibik and Zeitler, 2016), broadband di-
electric spectroscopy (Grzybowska et al., 2016) and X-ray dif-
fractometry (Thakral et al., 2016) and the reader is referred to the re-
spective reviews.
The stabilization of the drug in amorphous form can be obtained by
using polymers (Ubbink, 2016), mesoporous silica (Mura et al., 2019),
or by preparing co-amorphous formulations with a second drug or low
molecular weight excipient (Dengale et al., 2015). The polymers have
been the most widely used excipients for stabilization of amorphous
drugs by forming molecular dispersion with the drug and thereby
limiting the mobility of the drug molecules, which, in turn, inhibits
crystal growth and nucleation (Liu et al., 2015). Here the Tg of the
polymer matrix is of utmost importance and Tg≥ 50 °C has been re-
commended in order to compensate the plasticizing effect of the drug
and ambient moisture (Hancock et al., 1995).
The application of the ASD concept, as well as some of the important
stability issues are illustrated in the recent study of Knopp et al. (2018),
who prepared an ASD of celecoxib with polyvinylpyrrolidone (PVP) by
melt quenching. The ASD formulation increased dramatically drug
dissolution rate and resulted in considerable supersaturation, as com-
pared to the crystalline drug: the dissolution area under the curve at 4 h
(in vitro AUC0–4h) of the ASD formulation was 67.2 ± 0.3mg·min/mL,
compared to 12.8 ± 0.3mg·min/mL for the crystalline drug. This ef-
fect translated into a≈ 3-fold higher in vivo exposure in rats: AUC of
294 ± 16 μg·h/mL of the ASD formulation, compared to
105 ± 10 μg·h/mL for the crystalline drug. To study the effect of the
drug crystallization, which could occur during storage, the authors
varied the fraction of crystallized drug by preparing mixtures of the
pure ASD and the crystalline drug at different ratios. Although the in
vivo AUC decreased linearly with increasing the crystallized celecoxib
fraction, the difference between the pure celecoxib ASD (0% crystalline
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drug, AUC=294 ± 16 μg·h/mL) and 40% crystalline celecoxib
(AUC=258 ± 9 μg·h/mL) was not statistically significant, see Fig. 1.
Significant decrease in the AUC was observed upon further increase of
the crystalline celecoxib to 60%: AUC=198 ± 21 μg·h/mL. The in vivo
behavior of the formulations with different content of phase-separated
amorphous drug domains showed a similar pattern, see the red circles
in Fig. 1: no significant difference in the AUC was observed up to 40%
phase-separated amorphous celecoxib fraction, followed by a sig-
nificant decrease in the AUC at 60% amorphous fraction. Hence, the
obtained results suggested that the partial transformation of an amor-
phous drug to crystalline state or phase-separate amorphous domains
will not have significant effect on the in vivo exposure.
One should stress, however, that an important aspect of the ASD
techniques is the time window of sustained supersaturation, which
drives drug absorption and bioavailability. The rate of precipitation and
the possible approaches to kinetically trap the system in this thermo-
dynamically unstable state will be discussed in Section 2.3., as well as
the supersaturation advantage if amorphous precipitate is formed
(Section 2.4).
2.2.3. Solubilization in surfactant micelles
Surfactants are frequently encountered in classical and enabling
formulations (e.g. lipid-based formulations) and contribute to the drug
solubility enhancement in the carrier systems, as well as after appli-
cation. In addition, the drug is solubilized by the endogenous surfac-
tants (bile salts, phospholipids) present in the intestine. Hence,
understanding the main factors and mechanisms governing micellar
solubilization is required for successful application of surfactants in the
complex enabling formulations used in oral drug delivery.
Drug solubilization occurs above the surfactant critical micelle
concentration (CMC), where the surfactant molecules form micelles
(Rosen, 2004): colloidal aggregates with heterogeneous microstructure,
which contain regions with different polarity. The varying polarity in
the micelles facilitates the incorporation of poorly water-soluble drug
molecules, which results in solubilization, viz. the increase in the ap-
parent aqueous solubility of the drug. The CMC is also directly linked to
the stability of the micelles upon dilution in biological fluids: in gen-
eral, surfactants with low CMC values (CMC≪ 1mM, e.g. some non-
ionic surfactants, amphiphilic polymers) are more stable.
The solubilization of drugs by surfactant micelles in simple aqueous
solutions is an extensively studied topic (Bhat et al., 2008; Bodor, 1984;
Krishna and Flanagan, 1989; Ong and Manoukian, 1988; Park and Choi,
2006; Stoyanova et al., 2016; Ullah et al., 2014; Vinarov et al., 2018b;
Vinarov et al., 2018a; Vinarov et al., 2018d). Significant increase in
drug solubilization capacity with increasing surfactant chain length is
documented for several surfactant families (alkylsulfates, alkyl-
trimethylammonium bromides, alcohol ethoxylates, polysorbates) and
for drugs with diverse structures, such as steroids (Ong and Manoukian,
1988; Vinarov et al., 2018a; Vinarov et al., 2018d), benzophenones
(Vinarov et al., 2018d), benzimidazole (Vinarov et al., 2018b), mac-
rocyclic lactones (Bhat et al., 2008), sesquiterpene lactones (Krishna
and Flanagan, 1989) anthranilic and propionic acid derivatives
(Stoyanova et al., 2016; Ullah et al., 2014). The effect of surfactant
hydrophilic head group depends on the specific drug-surfactant inter-
actions: in the case of electrostatic attraction, the solubility can be in-
creased by several orders of magnitude (as shown for weakly basic
(Vinarov et al., 2018b) and acidic drugs (Park and Choi, 2006)),
whereas ion-dipole interactions also increase drug solubilization, but to
a lesser extent (Vinarov et al., 2018a; Vinarov et al., 2018d).
A major challenge in the context of solubility enhancement via
surfactant solubilization is the colloidal instability of the drug loaded
micelles when they are introduced into a medium containing bile salt. A
recent study on the behavior of conventional surfactant micelles in
biorelevant media showed that several drugs (fenofibrate, danazol and
progesterone) precipitated when ionic surfactant micelles were in-
troduced in bile salts-containing dissolution media, due to formation of
mixed micelles with low solubilization capacity. In contrast, poly-
sorbate surfactant micelles did not form mixed micelles and remained
stable, see Fig. 2 (Vinarov et al., 2018c). Hence, systematic studies in
biorelevant media in the presence of bile salts are required to clarify the
role of surfactant micelles in the solubility enhancement techniques for
oral delivery.
A recent study differentiates between the effect of diacyl- and
monoacyl phospholipids on the solubilization of celecoxib and its
Fig. 1. Relationship between the fraction of crystalline (blue squares) or
amorphous phase-separated (red circles) celecoxib (% w/w) in the ASDs and in
vivo AUC0-24 h ± SEM (n=3–5). (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this
article.)
Reproduced from Knopp et al. (2018).
Fig. 2. Illustration of the fate of drug-loaded micelles
in biorelevant medium. Drug-loaded micelles of
surfactants and bile salts were prepared separately
and then mixed at a 1:1 ratio. The solution of Tween
20+bile remained clear, whereas precipitation was
observed in the mixtures of bile salts with ionic
surfactants. The coexisting bile salt and Tween 20
micelles were determined by 1H DOSY.
Reproduced from Vinarov et al. (2018c).
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impact on in vitro permeability (Jacobsen et al., 2019). The authors
showed that the solubility enhancement of the monoacyl system was
significantly better, compared to the diacyl. The solubility enhance-
ment was maintained also in presence of bile salts (FaSSIF) for both
studied phospholipid types, which indicated that they have good sta-
bility in biorelevant media. However, no significant difference was
observed in the rate of permeation in a side-by-side setup, which in-
dicated that the process was controlled by the concentration of free
drug and not the apparent drug solubility.
2.2.4. Lipid-based formulations
The formulation of drugs in a lipid carrier system composed gly-
cerides, surfactants and co-solvents has attracted significant attention
due to the markedly increased drug oral bioavailability (Porter et al.,
2007). Apart from the solubility enhancement effect, the mechanism of
improved bioavailability of lipid-based formulations (LBF) is attributed
also to increased intestinal absorption via supersaturation (Gao and
Morozowich, 2006) and reduced first-pass effect via lymphatic trans-
port (Trevaskis et al., 2008).
LBF are primarily applied for BCS Class II and Class IV drug
substances, which are characterized by solubility-limited absorption.
The lipid formulation classification system (LFCS) separates LBF in 4
main types, depending on LBF composition, see Table 1 (Pouton, 2006).
Each type is characterized by a set of advantages and drawbacks.
For example, the glyceride-rich types 1 and 2 usually have poor drug
solvent capacity but are unlikely to lose that solvency upon dispersion
in the intestinal fluids, whereas the solvent- and surfactant-rich LBF
types III and IV can dissolve higher drug concentrations but suffer from
significant phase changes and potential drug precipitation upon dis-
persion. One aspect of LBF is that a significant fraction of the surfac-
tants used may be digestible, which should be considered during for-
mulation development (Vithani et al., 2017). The different formulation
strategies and the materials used are described in detail in several
dedicated reviews (Hauss, 2007; Pouton and Porter, 2008).
However, as the oral absorption depends on the intestinal con-
centration of dissolved drug, another LBF classification related to for-
mulation performance has been proposed (Williams et al., 2014b). The
latter groups LBF into four grades (A, B, C and D) where grade A pro-
vides the most robust solubility enhancement after dispersion and di-
gestion, whereas drug precipitation is expected with increasing
Table 1
The lipid formulation classification according to Pouton (2006).
Excipients in formulation Content of formulation (%, w/w)
Type I Type II Type IIIA Type IIIB Type IV
Oils: triglycerides or mixed mono- and diglycerides 100 40–80 40–80 <20 –
Water-insoluble surfactants (HLB < 12) – 20–60 – – 0–20
Water-soluble surfactants (HLB > 12) – – 20–40 20–50 30–80
Hydrophilic cosolvents (e.g. PEG, propylene glycol, transcutol) – – 0–40 20–50 0–50
Fig. 3. Top left: Chemical structures of tolfenamic acid and the cationic surfactant didodecyl ammonium bromide, DDAB. Top right: Composition of the model type
IIIB MC-SNEDDS used in the study. Bottom: Prospective overview of the fate of drug, lipid, and surfactant during in vitro dispersion and digestion.
Reproduced from Khan et al. (2018).
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probability and rate at the lower grades. The best systems usually
provide a transiently stable supersaturated drug solution that leads to
enhanced oral absorption (Anby et al., 2012). Another approach is to
maintain a supersaturated drug concentration in the LBF itself.
The LBF behavior in the gastrointestinal (GI) tract is extremely
complex. The reason is that on one side, the LBF carries a significant
diversity in its chemical composition: main lipid or lipid mixtures, co-
solvents, surfactant mixtures, drug load. On the other hand, a time-
dependent structural complexity is observed after dilution in the GI
fluids. For example, the drug can reside in different colloid species
(micelles, vesicles, emulsion droplets), it can precipitate in a crystal or
amorphous state, it can form a meta-stable supersaturated solution, or a
combination of the above (which is usually the case). A good illustra-
tion of the interplay between the excipients used for LBF formulation,
solubility enhancement, precipitation and solid-state properties is pro-
vided in the recent publication by Khan et al. (Khan et al., 2018). The
authors showed that the solid-state properties of a tolfenamic acid
precipitate during an in vitro digestion assay of a LBF depend on its
composition: an amorphous precipitate, linked to significantly higher
solubility and supersaturation was obtained when a cationic surfactant
was present in the LBF. Even more importantly, the mechanism of
amorphization was related to the formation of an ionic liquid-type of
associated between the oppositely charged drug and surfactant mole-
cule, which demonstrates the multifaceted behavior of the system, see
Fig. 3.
Therefore, an in-depth characterization of the behavior of LBF by in
vitro dispersion and digestion methods, as well as by in vivo studies, in
combination with the corresponding analytical techniques is required
(Larsen et al., 2011; Jørgensen et al., 2018; Williams et al., 2012b). The
latter have led to improved understanding of the system, which is used
to guide the formulation optimization, as described in detail by Feeney
et al. in a recent review (Feeney et al., 2016).
There are at least two drawbacks of LBF that need to consider in
drug development. The first one is related to the problems with low
drug loading in the LBF matrix, especially for brick dust molecules (e.g.
itraconazole) that are characterized by low aqueous and lipid solubility.
This challenge could be addressed by the hydrophobic ionic liquids
concept, as shown by Williams et al. for itraconazole and danazol,
which were dissolved in nicotinic acid-based ionic liquids and for-
mulated as LBFs (Williams et al., 2014a). The other issue is related to
the in vitro-in vivo correlation: as described in Section 5.2, the type of in
vitro experiment and the media should be carefully selected in order to
obtain good IVIVC. An industrial perspective on the current challenges
in LBF development, such as oxidation stability of the drug, capsule
compatibility, solidification of LBFs and others, is presented in the re-
cent review by Holm (2019).
2.3. Avoidance of precipitation
Most of solubility enhancement techniques provide an increase in
the apparent drug solubility by incorporation of drug molecules into
nano-sized structures, such as mixed micelles, liposomes, and molecular
inclusion complexes, or by using complex lipid vehicles (LBF).
However, once the formulation enters the GI tract, it is diluted and
encounters a complex environment of pH changes, hydrolytic enzymes
and bile salts. The latter usually results in rapid loss of the solubilization
capacity of the formulation and formation of a supersaturated meta-
stable drug solution (Gao and Morozowich, 2006; Jannin, 2018). Su-
persaturated drug solutions can also be obtained when solid drug in
ASD or cocrystal form is dispersed in the GI fluids (Frank et al., 2012a,
b; Taylor and Zhang, 2016). The main characteristic of supersaturated
solutions is the higher chemical potential of the drug molecules, com-
pared to solutions at or below the equilibrium solubility. This feature
can significantly increase the drug flux across the intestinal wall due to
the higher concentration and the chemical potential gradient, thus in-
creasing oral drug absorption (Anby et al., 2012; Gao and Morozowich,
2006; Taylor and Zhang, 2016). On the other hand, supersaturation can
also cause drug precipitation (Mohsin et al., 2009) until the equilibrium
solubility (determined with respect to the stable crystal form of the
drug, see Section 4.1.) is reached. However, as long as the intestinal
rate of absorption is higher than the rate of precipitation, drug ab-
sorption dominates, and in vivo precipitation will be limited. In addi-
tion, if the rate of precipitation is controlled and is sufficiently slow, the
supersaturation window can significantly increase drug absorption and
oral bioavailability. The concept of a drug formulation that provides
significant and sustained supersaturation is termed “spring and para-
chute” approach (Brouwers et al., 2009). The approaches to prevent
precipitation by using excipients, which provide the “parachute” effect,
will be briefly described below. For more information about the nature
of the supersaturated systems and their applications in drug delivery,
the reader is referred to recent review articles (Brouwers et al., 2009;
Laitinen et al., 2017; Taylor and Zhang, 2016).
There are two main approaches to avoid drug precipitation: (1)
decrease the degree of supersaturation or (2) stabilize the super-
saturated state by use of precipitation inhibitors. The first approach can
be realized in several ways. For example, solubilizers which act as
thermodynamically stable reservoirs for the drug molecules can be in-
troduced (e.g. surfactant micelles, cyclodextrins) and some are natively
present in the gut (bile salt aggregates, phospholipid vesicles) (Taylor
and Zhang, 2016). Another way is to slow the drug release by using
sustained-release formulations, so that a moderate supersaturation with
lower drive for precipitation is maintained (Augustijns and Brewster,
2012). Such slow-release formulations may contribute an additional
increase of oral bioavailability relative to their quick-release, non-pre-
cipitating counterparts (Six et al., 2005).
The most widely applied strategy to maintain supersaturation is to
use precipitation inhibitors, such as polymers, low molecular weight
surfactants (both as solubilization enhancer and precipitation inhibitor,
Chen et al., 2015) or cyclodextrins (Brouwers et al., 2009). Among
these, polymers are the most frequently used and the most studied ones
(Warren et al., 2010). Several mechanisms of action have been pro-
posed to explain the action of the precipitation inhibitors, all of which
are related to modification of the nucleation and/or crystal growth
stages by adsorption or complexation (Laitinen et al., 2017; Warren
et al., 2010). Warren et al. studied a large set of polymers to unravel the
link between the polymer molecular structure and its ability to sustain
supersaturated drug solutions (Warren et al., 2013). Electrostatic at-
traction between the oppositely charged drug and the polymer was
found to significantly delay precipitation, whereas the precipitation
was induced when the species were similarly charged. Enhanced pre-
cipitation was observed also for polymers which are rich in primary
amine, amide, carboxylic acid, and hydroxyl functional groups. Positive
effect of ether groups was documented for halofantrine and meclofe-
namic acid.
Although the majority of studies in the area of polymeric pre-
cipitation inhibitors (PPI) are performed in the in vitro settings, a
number of recently published investigations show that the PPI are also
effective in vivo (Suys et al., 2018; Feng et al., 2018; Jaisamut et al.,
2018; Quan et al., 2017). For example, Suys et al. determined the
ability of a number of PPI to maintain the supersaturation during in
vitro digestion of a fenofibrate LBF and then coupled the in vitro di-
gestion assay with an in situ single pass rat intestinal perfusion model
(Suys et al., 2018). The results showed good correlation between the
PPI-mediated in vitro supersaturation and the in vivo exposure, thus
confirming the functionality of the PPI and the relevance of the in vitro
assay.
There are a number of drug delivery methods (ASD, LBF, some
pharmaceutical salts) that yield supersaturated drug solutions after oral
administration and have been described in Section 2.2. In addition,
several excipient families that help to avoid drug precipitation in the
gut are also available, the PPI being the most studied ones. In this re-
spect, it is vital to keep in mind that the supersaturated state needs to be
B.J. Boyd, et al. European Journal of Pharmaceutical Sciences 137 (2019) 104967
7
stabilized only on a time scale relevant to drug absorption. Further in
vivo and in vitro studies of supersaturated systems in non-sink conditions
(Augustijns and Brewster, 2012; Sun et al., 2016) are required to pre-
cisely define the supersaturation window for easily permeable (BCS
class II) and poorly permeable drugs (BCS class IV). Recently, a stan-
dardized method for assessing supersaturation propensity of drugs in
biorelevant media has been developed. The method assesses the time
for supersaturation (induction time) and the rate of precipitation at four
degrees of supersaturation, the highest being the apparent maximum
degree of supersaturation. By use of classical nucleation theory, the
susceptibility of given drug to precipitation or supersaturation can be
assessed, as well as the suitability for polymers to prolong the induction
time or reduce the rate of precipitation (Palmelund et al., 2016; Plum
et al., 2017).
2.4. Building of high absorptive concentration gradients
An important mechanism to promote absorptive flux of drugs is to
achieve high drug concentration gradients across the intestinal wall
(Brouwers et al., 2009). For poorly water-soluble drugs, there is a first
formulation strategy that primarily aims at high luminal super-
saturation of drug, while another approach emphasizes spatial aspects
by targeting either specific segments of the intestine for site-specific
absorption or the rationale is to target the mucosa specifically to
achieve high local concentrations close to the brush border membrane
of enterocytes. Regarding the first strategy of achieving generally high
luminal drug concentrations, different supersaturating formulations are
of interest, such as LBF, solid dispersions, or some colloidal delivery
systems (Kawakami, 2012). Drug supersaturation is generally not only
the result of formulation technology but is further determined by fac-
tors of the GI tract. There is a physiology-enabled supersaturation that
is pH-driven and can be given with simple formulations of drug salts or
it plays a role in supersaturating systems (Brouwers and Augustijns,
2014; Hens et al., 2016a; Kourentas et al., 2016; Brouwers et al., 2018).
Such pH-driven physiology-enabled supersaturation can also occur with
some comedication or following consumption of acidic beverages
(Walravens et al., 2011; Knoebel and Larson, 2018).
Due to the metastable nature of drug supersaturation, the high
concentrations should be sustained for sufficiently long to profit from
high concentration gradients regarding absorptive flux. Therefore, it is
the interplay of supersaturation, precipitation inhibition and absorp-
tion, which makes this formulation approach viable for biopharma-
ceutical challenging drugs. The solubilization and permeation effects
have been modeled mathematically for cosolvent mixtures (Miller et al.,
2012), micellar formulations (Miller et al., 2011), and there is further a
model for the interplay of formulation digestion, supersaturation, and
permeation (Stillhart et al., 2014). These models reveal some me-
chanistic complexity and they indicate, for example, that highest drug
loading in the formulation may not generally entail optimal absorptive
concentration gradients. Examples of in vitro experimental proof are
found in Frank et al. (2012a) and Jacobsen et al. (2019).
To better understand how high absorptive concentration gradients
are obtained, it is important to better know about intestinal formulation
processing and hence the changes of any supersaturating system fol-
lowing oral administration. For lipid-based system, it is mostly the li-
polysis-triggered changes that have to be considered and in case of solid
dispersions, there should be sufficient knowledge about the different
particles that evolve in the course of aqueous dispersion (Friesen et al.,
2008). Following early experimental reports on the spontaneous for-
mation of amorphous, drug-rich particles in aqueous dispersions of
amorphous solid dispersions (ASDs; Tho et al., 2010), their impact on
solubility (Frank et al., 2012b) and permeation (Frank et al., 2012a),
the influence of drug-rich particles emerging from itraconazole solid
dispersions was studied in more detail in vitro and regarding oral
bioavailability in rats (Stewart et al., 2017a). The authors concluded
that solid dispersions of BCS 2 drugs should be designed specifically for
the emerging colloidal species so that high absorptive concentration
gradients can be achieved. This is in line with research of Lynne Taylor's
group in which effects of excipients and colloids were studied regarding
membrane flux that is based on thermodynamic drug activity (Raina
et al., 2015). Drug permeation through a membrane has been therefore
used as a marker of thermodynamic drug activity that can be reduced
not only by precipitation or a liquid-liquid phase separation but also
because of strong drug-excipient interactions and slow partitioning
from droplet or colloids, which may result during formulation proces-
sing in the GI tract.
A better understanding of emerging colloids from solid dispersions
or LBF in the intestine is also important regarding local effects. It was,
for example, shown that the acidic microclimate of the unstirred water
layer can promote absorption from intestinal mixed micelles since fatty
acids are better readily absorbed, which stimulates local super-
saturation and high local concentration gradients for drug permeation
(Yeap et al., 2013). Such local effects of colloids or particles from su-
persaturating formulations lead to the second strategy for high ab-
sorptive concentration gradients, in which spatial effects are targeted
deliberately.
Drugs often exhibit regional differences of intestinal permeability so
that site-specific concentration gradients are desirable to maximize oral
bioavailability (Masaoka et al., 2006). An absorption window may be
also widened as reported in the case of furosemide for which for-
mulations of Eudragit L increased absorption in distal segments of the
gastrointestinal tract (Terao et al., 2001). Site-specific concentration
gradients have been targeted since many years to deliver anti-in-
flammatory drugs for inflammatory bowel diseases (Klein et al., 2005).
Such controlled release systems, with targeting of an intestinal segment
or colon, represent a comparatively established formulation approach
(Basit and McConnell, 2011). By contrast, targeting specifically the
mucus and the brush border membrane is a rather dynamic field of
current research. The technical formulation challenges are here dif-
ferent for large active molecules as compared to small molecular drugs
(Sigurdsson et al., 2013). Due to the importance of the topic, a separate
section of this review is dedicated to mucus diffusion of drugs (5.5.).
There is knowledge about molecular polymer properties required to
achieve mucus adhesion (Peppas et al., 2009), which may be applied to
the idea of supersaturating polymeric micelles (Yu et al., 2013). Such
supersaturating colloids may emerge from LBFs or solid dispersions,
which emphasizes again the idea that designed colloids from super-
saturating formulations provide an attractive formulation rationale. In
case of solid dispersions, any such system that combines amorphous
solid dispersion with an intended controlled release behavior has been
named previously a 4th generation of solid dispersions (Vo et al., 2013).
More research in this field will be likely conducted in upcoming years
with a particular aim to achieve high absorptive concentrations gra-
dients.
3. In silico methods: computational modelling and simulation of
performance
Computational assessment of drug performance in the GI tract has
mainly revolved around drug dissolution/solubility and permeation,
evaluations of disintegration and dissolution of, and release from, do-
sage form. Insights into solubility, permeability and combinations
thereof have been extensively reviewed recently (Bergström and
Larsson, 2018; Bergström et al., 2016; Matsson et al., 2016). Here we
focus on presenting some of the recent work making use of molecular
dynamics simulations (MDS) to understand intestinal solubilization and
performance of advanced drug delivery systems such as LBF and
amorphous solid dispersions (ASD).
MDS have during the last years gained interest in pharmaceutical
sciences and entered into the analysis of dosage form performance.
Molecular dynamic schemes can be implicit, i.e. the methods used are
continuum-based and treat the surrounding solvent as an isotropic
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continuous medium, or explicit, i.e. each solvent is presented at a mo-
lecular level. A drawback of the implicit simulation methods is that the
atomistic level is lost. On the other hand, the explicit solvation
methods, which explicitly consider solvent-specific effects and solute-
solvent interactions and therefore, at least theoretically, be more ac-
curate and provide better information about solvation, is computa-
tionally costly and simulations are time consuming. This is primarily
because of the high degree of freedom from the explicit solvent mole-
cules. More information around the MDS methodologies can be found
in these recent papers (Bernardi et al., 2015; Szilárd et al., 2015;
Ganesan et al., 2017). Performance evaluation in the GI tract is often
simplified to evaluation of dosage forms in simple water models when
studied computationally. However, relative solubilization of a number
of drugs has been studied making use of MDS. Holmboe et al. made
simulations of the lipid structures formed by bile components (phos-
pholipids and taurocholate) and studied the partitioning of danazol,
felodipine and carbamazepine into the lipid bilayers formed. It was
concluded that the relative solubilization was strongly related to the
capacity of the drug molecule to form hydrogen bonds with the taur-
ocholate (Holmboe et al., 2016).
LBF is one advanced drug delivery system that has been studied by
MDS with focus on dispersion and digestion of LBF. Pouton et al. have
used MDS and all atom methodology to study phase changes upon
dispersion and digestion and the resulting impact on solubilization. In
one study they used danazol as the poorly water-soluble model com-
pounds and solubilization capacity was simulated in response to di-
gestion of a simple LBF (long-chain triglyceride) (Birru et al., 2017a).
The simulations showed that the solubilization, and hence, the solubi-
lity, of danazol increased with increased digestion; these results were in
agreement with the experimental data obtained for the same compo-
sition of digested material. In two other studies they explored how the
digestion of lipids may influence the colloidal structures formed in the
intestinal fluid, and to what extent cholesterol and pH influences the
aggregation of intestinal lipids (Birru et al., 2017b; Suys et al., 2017). In
a more recent study, the same group studied the location of probe
molecules in a non-ionic surfactant (Warren et al., 2019). The micelles
were composed of octaethylene glycol monododecyl ether, which has a
C12 alkyl chain linked to a pegylated chain. The simulations showed
that cyclic compounds were moved out from the micelle core, polar
groups anchored the compounds in the micelle interface with the water
and aromaticity resulted in exclusion of the compound from the mi-
cellar core. Drug localization has also been studied by Benson and Pless.
They simulated mixtures of mono-, di- and triglycerides to mimic di-
gestion and to what extent that influenced the location of the poorly
water-soluble drug cyclosporine. It was shown that when the mono-
glyceride concentration increases the cyclosporine relocated to the core
region of triglyceride moieties (Benson and Pleiss, 2014). A related
study by Larsson et al. showed that the phase transitions that occur in
response to dispersion of LBF in water can be reproduced using coarse-
grained molecular dynamics (Larsson et al., 2017). Changing the re-
solution of the molecular structures from all atom to coarse grained
results in that larger systems can be studied, and hence, e.g. solubili-
zation of drug molecules can be studied under physiologically relevant
conditions. In particular, relevant conditions of lipidic components (i.e.
bile components and ingested lipids included in food or formulations)
can be studied.
Another advanced formulation strategy that has been explored with
MD simulations is ASD. Xiang and Anderson have studied such systems
in a series of papers, with the main focus being on the physical stability
of the ASD rather than the performance upon dissolution in e.g. the GI
tract. They have studied different model compounds (indomethacin,
ibuprofen, felodipine and the small peptide Phe-Asn-Gly) and polymers
(hydroxypropyl methyl-cellulose, hydroxypropyl methyl-cellulose
acetate succinate, poly(D,L-lactide), polyvinylpyrrolidone, poly-
vinylpyrrolidone-co-vinyl acetate, polyvinylalcohol) (Xiang and
Anderson, 2004, 2005, 2013a, b, 2014, 2019) for properties such as
internal hydrogen bond pattern, water mobility, glass transition tem-
perature, mobility and miscibility. While some of the properties did not
result in quantitative values in agreement with those determined ex-
perimentally (e.g. glass transition temperature) others were in good
agreement with experimental data (e.g. water diffusion and identifica-
tion of the functional groups (type and quantity) involved in the hy-
drogen bonds in the amorphous solid) (Xiang and Anderson, 2013a;
Yuan et al., 2015). Performance-wise, Edueng et al. studied the me-
chanism of action for stabilization of ASD upon dissolution in water.
They concluded that the hydrogen bond patterns between the drug-
drug molecules, drug-water molecules and drug-polymer molecules
were strongly influencing the extent to which a polymer will stabilize
the supersaturation formed (Edueng et al., 2017). Similarly, Sun et al.
used dissipative particle dynamics (DPD) to obtain molecular insights
into the dissolution of lacidipine formulated with Eudragit E100 as an
amorphous solid dispersion with 20% drug load. DPD is a coarse-
grained strategy based on beads that clusters atoms and presents the
molecular structure in a low resolution; these simulations can therefore
be used to computationally study flexibility and mobility of long
polymer chains over longer time spans. They found that the experi-
mentally observed rapid release at pH 1.2 was a result of swollen mi-
crostructures whereas the slow dissolution at pH 6.8 was an effect of the
formation of compacted microstructure of aggregated amorphous par-
ticles (Sun et al., 2017).
4. In vitro methods: compendial techniques used to evaluate the
availability of small molecules from drug delivery systems
Techniques described in Pharmacopeia to evaluate the availability
of poorly water-soluble drugs from drug delivery systems are limited to
the measurement of drug solubility in various aqueous media and to the
evaluation of dissolution/drug release from these systems.
4.1. Solubility measurement in buffers and biorelevant media
Solubility is the concentration limit, at thermodynamic equilibrium,
to which a solute is uniformly mixed into a solvent
(< 1236>Solubility Measurements. 2017.Pharmacopoeia Forum. 43
(2), 1–17.). In common practice, thermodynamic solubility is also re-
ferred as equilibrium solubility (i.e. the concentration limit is reached at
thermodynamic equilibrium) or saturated solubility (i.e. a saturated
solution is used to ascertain that the concentration limit is achieved).
Two other solubilities can be measured: apparent solubility and in-
trinsic solubility. Apparent solubility is the concentration experimen-
tally measured of a solute in a solvent out of equilibrium conditions.
The apparent solubility can be higher than equilibrium solubility if the
drug delivery system generates supersaturation or it can be lower than
equilibrium solubility if the time needed to reach equilibrium is in-
sufficient. Intrinsic solubility is the concentration of the uncharged
(neutral) solute in a solvent and can be measured in a specific pH range
where the uncharged molecules are dominant.
In the current edition of the United States Pharmacopeia (USP) and
European Pharmacopeia (EP) the method described to determine the
solubility of drugs is limited to the evaluation of the ‘approximate so-
lubility’ of the drug substance - the number of parts of solvent required
to dissolve one part of solute (Description and relative solubility of USP
and NF articles. 2018. United States Pharmacopeia 41 (First
Supplement), 8516). In the table provided to describe solubility of
drugs, the term ‘poorly soluble’ is not listed and other descriptive terms
such as sparingly, slightly, very slightly soluble or practically insoluble
are used.
Solubility can be performed in the dissolution medium described in
the drug product monograph or in generic media such as simulated
gastric fluid (SGF) or simulated intestinal fluid (SIF) – the only two
media purposely simulating gastrointestinal fluids currently listed in
USP tests solutions (Test solutions. 2018. United States Pharmacopeia
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41, 5750–5761). Compositions of these two fluids are listed in Table 2.
The main composition difference of these media with regular buffer
solutions is the addition of enzymes (pepsin and pancreatin) that can
modify the behavior of drug products, in particular those in gelatin
capsules. However, these media cannot be considered as biorelevant as
they do not contain any biliary components (phospholipids, bile salts,
etc.) or food components.
A new monograph on solubility measurements is currently under
revision (2017) for inclusion in USP. This new chapter describes factors
affecting the solubility of drug in various aqueous media (e.g. pH, salts
and counter-ions, co-solvents, surfactants) and the typical experimental
methods used to assess drug solubility.
The USP monograph on solubility measurements recommends one
method to measure equilibrium solubility of drugs, this is the saturation
shake-flask method (2017). This method is reliable and widely used in
the pharmaceutical industry to measure solubility of drug substance in
aqueous media as well as in excipients (Williams et al., 2012b). The
drug substance is added in excess to a solubility medium in a flask or
vial. The suspension is mixed for 24 h in a temperature-controlled en-
vironment such as a shaking incubator. Then the excess (undissolved)
solid is separated from the solution by sedimentation or centrifugation.
The concentration of drug dissolved in the supernatant is assayed and
equilibrium solubility is reached when multiple samples assayed after
different equilibration time periods give equivalent results. The equi-
librium solubility can be confirmed by assaying another sample after an
additional 24 h of shaking, taking into account the stability of the
medium. The same experimental set-up can be applied for the mea-
surement of drug solubility in biorelevant media at 37 °C. The USP
monograph on solubility measurements describes a series of methods to
determine the apparent solubility of drugs, e.g. by potentiometric ti-
tration, turbidimetry. The monograph also addresses the miniaturiza-
tion, high-throughput, and automation of these solubility measure-
ments.
Biorelevant media have been developed to better estimate drug
solubility in gastric or duodenal environment in the presence or absence
of digested food components. Good correlation between solubilities
measured in biorelevant media and in human gastrointestinal fluids has
been reported (Vertzoni et al., 2005). To better match solubilities in
human fluids various versions of biorelevant media were proposed and
their physical-chemical properties (pH, surface tension, osmolality and
buffer capacity) were adjusted (Dressman et al., 1998; Jantratid et al.,
2008; Marques et al., 2011). Recently Markopoulos et al. (2015) pro-
posed a decision tree to select the appropriate level of complexity of
biorelevant media depending on the type of drugs, dosage forms and
dosing conditions. Four levels of simulation of luminal compositions
were proposed:
• Level 0 media are simple aqueous solutions where the pH is adjusted
to mimic the pH of specific intestinal region. The compendial buffer
solutions and SGF or SIF without enzymes described above could be
used as level 0 media.• Level I media mimic both the pH and buffer capacity of specific
intestinal region.• Level II media comprise in addition to above, bile components,
dietary lipids, lipid digestion products and have an adjusted os-
molality. These compositions better reflect the solubilization capa-
city of luminal fluids and the impact of fasted/fed dosing conditions.• Level III media contain dietary proteins and enzymes (in place of
digestion products from Level II) to address the impact of digestion
and viscosity on the drug release.
The two most simple media (0 and I) are proposed for water-soluble
compounds (BCS class I and III). Authors recommended the use of Level
II media for the evaluation of the solubility of poorly water-soluble
drugs (BCS class II and IV). Finally, the use of the most complex Level III
media is proposed for enabling formulations where the composition can
change overtime (e.g. LBFs) and to check the luminal stability of the
drug and dosage form (Markopoulos et al. 2015).
Compositions of biorelevant media selected by USP (Jantratid and
Dressman, 2009; Marques, 2011) are listed in Table 3.
It should be noted that the proposed USP compositions do not
correspond to the biorelevant media recently reviewed by Markopoulos
et al. (2015). The Level II compositions related to the USP proposed one
Table 2
Compositions of simulated gastric fluid (SGF) and simulated intestinal fluid
(SIF).
Ingredient Composition
SGF
pH=1.2
SIF
pH=6.8
Sodium chloride 2.0 g –
Pepsin 3.2 g –
Hydrochloric acid 7mL –
Monobasic potassium phosphate – 6.8 g
Sodium hydroxide 0.2 N – 77mL
Pancreatin – 10 g
Water q.s. 1000mL q.s. 1000mL
Table 3
Compositions of human biorelevant media. FaSSGF: Fasted-state simulated gastric fluid; FeSSGF: Fed-state simulated gastric fluid; FaSSIF-v2: Fasted-state simulated
intestinal fluid (version 2); FeSSIF-v2: Fed-state simulated intestinal fluid (version 2); SCOF-2: Simulated colonic fluid (Jantratid and Dressman, 2009; Marques,
2011).
Ingredient USP composition
FaSSGF
pH=1.6
FeSSGF
pH=5
FaSSIF-v2
pH=6.5
FeSSIF-v2
pH=5.8
SCOF-2
pH=5.8
Hydrochloric acid q.s. to pH 1.6 q.s. to pH 5 – – q.s. to pH 5.8
Sodium chloride 34.20mM 237.00mM 68.60mM 125.50mM –
Sodium taurocholate 0.08mM – 3.00mM 10.00mM –
Lecithin 0.02mM – 0.20mM 2.00mM –
Pepsin 0.1 g – – – –
Sodium hydroxide – q.s. to pH 5 34.8mM 81.65mM –
Sodium acetate – 29.75mM – – –
Acetic acid – 17.12mM – – 170mM
Milk, whole – 1:1a – – –
Maleic acid – – 19.12mM 55.02mM –
Glyceryl monooleate – – – 5.00mM –
Sodium oleate – – – 0.80mM –
a Prepare the acetate buffer and mix 1:1 with whole milk.
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are listed in Table 4. The main differences are highlighted by grey
shading.
Recently another approach has been taken to simulate the compo-
sition of the gastrointestinal fluids. Based on literature reviews of the
composition of intestinal fluids, design of experiments (DoE) have been
applied to develop a set of media that can represent the environment
that a drug is encountering during transit of the GI tract (Khadra et al.,
2015; Madsen et al., 2017). This gives a reflection of the solubility of
the drug in the intestinal environment and which factors (bile salt,
phospholipids, pH, etc.) that are important for its solubility. Further,
since DoE is used, an algorithm describing the solubility of the drug
within the design space can be determined (Madsen et al., 2017).
4.2. Dissolution testing
During drug development, in vitro dissolution methods are applied
to optimize the delivery profile of the dosage form. A prerequisite for
the utility of this is that the selected in vitro methods are predictive of
the in vivo outcome. The conventional dissolution equipments described
in the current edition of the United States Pharmacopeia (USP) and
European Pharmacopeia (EP) for the dissolution of drug substance from
oral drug delivery systems are: basket (apparatus 1), paddle (apparatus
2), reciprocating cylinder (apparatus 3), and flow-through cell (appa-
ratus 4) (< 711>Dissolution. 2018. United States Pharmacopeia 41,
6459–6469). The choice of the apparatus and the dissolution media is
specified in the individual monograph of dosage forms administered
orally. Most commonly, dissolution tests are performed in either ap-
paratus 1 or 2 with buffer solutions. These buffer solutions are selected
to obtain sink conditions, i.e. conditions where the equilibrium solu-
bility of the drug in the dissolution medium is at least three times
higher than the actual drug concentration. These conditions are not
possible with poorly water-soluble drugs when using simple buffer so-
lutions (Phillips et al., 2012). Indeed, the volume of dissolution medium
needed to dissolve the dose of the drug substance would be very high
and more than the volume of the classic 1 L vessels. To overcome this
limitation, various options are possible by selecting another apparatus
or modifying the dissolution medium. The selection of apparatus 4 in
the open loop configuration allows using large amount of dissolution
medium and maintaining sink conditions in the flow-through cell where
the dosage form is held. The modification of the dissolution medium
can also increase the solubility of the drug substance by addition of
surfactants (above their critical micellar concentration), complexing
agent (e.g. cyclodextrins), or organic solvents (Phillips et al., 2012). The
major drawback for these two options is that the dissolution medium
composition and volume will not be biorelevant. Volumes of fluids in
the gastrointestinal tract are relatively low (Schiller et al., 2005;
Koziolek et al., 2014) in comparison to standard volume used in dis-
solution testing and do not contain organic solvent or complexing
agents.
In the last decades, several new drug classification systems have
been described to evaluate the potential difficulties of developing a
given drug. These classification systems are the Developability
Classification System (DCS) and the refined DCS, both based on the
dissolution rate and solubility of the drug in biorelevant media, as well
as the permeability (Butler and Dressman, 2010, Rosenberger et al.,
2018). These classification systems can be considered as extensions/
refinements of the BCS from 1995 (Amidon et al., 1995), which is only
considering solubility in buffers. Applying the guidelines of these
classification systems will facilitate identification of biopharmaceutics-
related challenges using simple, well-defined methods and thereby
evaluation of the likelihood of developing an in vitro biorelevant dis-
solution method, able to predict the in vivo performance (Rosenberger
et al., 2018).
The selection of composition of biorelevant media (e.g. Level II
biorelevant media, Georgaka et al., 2017), dissolution equipment and
procedure to achieve in vivo predictivity, is not simple and should be
based on the physicochemical properties of the drug and the desired
delivery principle and therapeutic profile (Markopoulos et al., 2015;
Madsen et al., 2017; Andreas et al., 2018; Löbenberg et al., 2000).
Nevertheless, it is not always possible using conventional dissolution
methods. Therefore, considering the many weak basic drugs in devel-
opment in the pharmaceutical industry, dissolution models encom-
passing a gastric dissolution step and transfer to small intestinal con-
ditions have been developed. These models often better predict the in
vivo performance of weak basic drugs in immediate release formula-
tions, as compared to conventional methods (Mathias et al., 2013;
Kourentas et al., 2016c).
Biorelevant conditions are well adapted for some drug delivery
systems where the drug is dispersed amorphous in a polymer matrix.
The drug is then released from the matrix and generates a concentration
of drug higher than its solubility in the dissolution medium (spring
effect) and then tends to precipitate overtime to reach equilibrium so-
lubility (parachute effect) (Brouwers et al., 2009). In these cases, the
combination of biorelevant in vitro data with physiologically-based
pharmacokinetic (PBPK) modelling is becoming more and more used, as
it enables assessment of in vivo pharmacokinetics, based on in vitro drug
behavior under physiologically relevant conditions (Kaur et al., 2018;
Kostewicz et al., 2014). By basing PBPK models on biorelevant in vitro
data from e.g. dissolution, solubility or supersaturation studies, it is
possible to improve the ability to predict the in vivo performance
Table 4
Selection of Level II biorelevant media compositions. FaSSGF: Fasted-state simulated gastric fluid; FeSSGF: Fed-state simulated gastric fluid; FaSSIF-v2: Fasted-state
simulated intestinal fluid (version 2); FeSSIF-v2: Fed-state simulated intestinal fluid (version 2); FaSSCoF: Fasted-state simulated colonic fluid (Markopoulos et al.
2015).
Ingredient Level II composition
FaSSGF
pH=1.6
FeSSGF middle
pH=5
FaSSIF-v2
pH=6.5
FeSSIF-v2
pH=5.8
FaSSCoF
pH=7.8
Hydrochloric acid q.s. to pH 1.6 q.s. to pH 5 – – –
Sodium chloride 34.20mM 181.70mM 68.60mM 125.50mM –
Sodium taurocholate 0.08mM – 3.00mM 10.00mM 0.15
Lecithin 0.02mM – 0.20mM 2.00mM 0.3
Pepsin – – – – –
Sodium hydroxide – q.s. to pH 5 34.8mM 102.40mM 120mM
Sodium acetate – 32.98mM – – –
Acetic acid – 18.31mM – – –
Lipofundin®/buffer – 8.75/91.25 – – –
Maleic acid – – 19.10mM 71.90mM 75.8mM
Glyceryl monooleate – – – 5.00mM –
Sodium oleate – – – 0.80mM 0.1mM
Tris 45.4 mM
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(Berthelsen et al., 2014; Pathak et al., 2017). As an example, Hens et al.
(2017b), applied in vitro data from biorelevant dissolution and super-
saturation propensity studies, as well as clinical intra-gastric observa-
tions, to a PBPK model and achieved a prediction of the in vivo PK
profile of posaconazole, dosed in two suspensions. Several PBPK models
are available (Simcyp, GastroPlus), and are continuously being further
developed (Kostewicz et al., 2014). However, more work is still needed
in order to understand which in vitro data are needed and how to im-
plement the data into the PBPK models.
However, these strategies cannot be yet applied to self-(nano)
emulsifying drug delivery systems (S(N)EDDS) where the drug is al-
ready in solution and/or when the formulation can be degraded by
enzymes (e.g. LBFs, SNEDDS). To address these limitations, advanced
characterization techniques were developed such as solubility mea-
surement/dissolution testing with human gastrointestinal fluids, lipo-
lysis testing for evaluating the impact of lipases on LBFs, and combined
dissolution/permeation techniques. These techniques will be described
in the following chapters.
5. State of the art methods: evaluation of the absorption/
availability of small molecules from drug delivery systems
5.1. Exploring the behavior of poorly water-soluble drugs in the human
gastrointestinal tract
The intestinal absorption of poorly water-soluble drugs is challen-
ging due to a limited intrinsic driving force for permeation across the
intestinal mucosa. In most cases, absorption is also prone to substantial
intra- and intersubject variability, since multiple gastrointestinal vari-
ables related to fluid composition, fluid volume, gastric emptying rate,
and motility, may affect the behavior of poorly water-soluble drugs and
the strategies that are used to enable their absorption. Therefore, an in-
depth understanding of the interactions between drug, formulation and
gastrointestinal physiology is critical to both the successful develop-
ment of oral drug products and the efficient use of drug products in
clinical practice. While multiple in vitro tools and in silico models are
available to simulate gastrointestinal drug behavior, their biorelevance
and predictive value often appear insufficient for poorly water-soluble
drugs. Research approaches that enable the evaluation of drugs in the
human gastrointestinal tract form the basis for an improved under-
standing of gastrointestinal processes critical for drug absorption and
for a knowledge-based optimization of simulation tools.
While imaging techniques (e.g. scintigraphy, magnetic marker
monitoring) are useful to monitor drug transfer and release, the eva-
luation of dissolution-related issues for poorly water-soluble drugs in
the human gastrointestinal tract requires the aspiration and analysis of
gastric and/or intestinal fluids following drug intake (Brouwers and
Augustijns, 2014). Over the past decade, several gastrointestinal as-
piration studies have been performed to study the intraluminal beha-
vior of poorly water-soluble drugs (Table 5). Here, we will focus on a
recent example that involves the gastrointestinal behavior of the highly
lipophilic and weakly basic drug itraconazole after administration of
either an HPMC-based solid dispersion (Sporanox® capsules) or a cy-
clodextrin-based solution (Sporanox® oral solution) to fasted healthy
Table 5
Overview of gastrointestinal aspiration studies in healthy volunteers studying the intraluminal behavior of poorly water-soluble drugs (BCS Class II or IV).
Drug (API) Dosage forms Intake conditionsa Samples Refs.
Amprenavir Solution based on co-solvents and surfactant TPGS
(1200mg, Agenerase® capsule)
Fasted state Duodenum, jejunum (Brouwers et al., 2006)
Prodrug (fosamprenavir 400mg, Telzir® tablet) Fasted vs fed state Stomach, duodenum
Systemic circulation
(Brouwers et al., 2007)
Itraconazole Solid dispersion (100mg, Sporanox® capsule) Fasted state Stomach, duodenum
Systemic circulation
(Brouwers et al., 2017)
Solution based on HP-β-CD (100mg, Sporanox® solution) Fasted state
With vs without water
intake
Stomach, duodenum
Systemic circulation
(Berben et al., 2017)
Posaconazole High-dose suspension (400mg, Noxafil®) Fasted state
Water vs cola
PPI comedication
Stomach, duodenum
Systemic circulation
(Walravens et al., 2011)
Low-dose suspensions (neutral vs acidified, 40mg,
Noxafil®), gastric dosing
Fasted state Stomach, duodenum
Systemic circulation
(Hens et al., 2016a)
Low-dose solution (20mg, Noxafil®), gastric dosing Fasted state Stomach, duodenum (Hens et al., 2016a)
Solid dispersion (100mg, Noxafil® tablet) Fasted vs fed state Stomach, jejunum
Systemic circulation
(Hens et al., 2016b)
Ketoconazole Acidified solution (100 vs 300mg), gastric dosing Fasted state Duodenum (Psachoulias et al., 2011)
Dipyridamole Acidified solution (30 vs 90mg), gastric dosing Fasted state Duodenum (Psachoulias et al., 2011)
Danazol Solution in a liquid meal (150mg), gastric dosing Fed state Duodenum (Vertzoni et al., 2012)
Fenofibrate Microparticles (200mg, Lipanthyl® capsule)
Nanoparticles (145mg, Lipanthylnano® tablet)
Fasted vs fed state Stomach, duodenum
Systemic circulation
(Hens et al., 2015)
Abiraterone Prodrug (abiraterone acetate 250mg, Zytiga® tablet) Fasted state
Fed state
Duodenum
Systemic circulation
(Geboers et al., 2016; Stappaerts et al., 2015)
Albendazole Aqueous-based suspension (50mg), with and without
precipitation inhibitor
Lipid-based suspensions
Fasted state Stomach, duodenum (Kourentas et al., 2016a)
Indinavir Sulfate salt (400mg, Crixivan®) Fasted vs fed state
PPI comedication
Stomach, duodenum (Rubbens et al., 2016)
Diclofenac Solution (50mg, Cataflam®) Fasted vs fed state
PPI comedication
Stomach, duodenum (van den Abeele et al., 2016)
Potassium salt tablet (50mg, Cataflam®) Fasted vs fed state Stomach, duodenum
Systemic circulation
(van den Abeele et al., 2017b)
Ibuprofen Tablet (800mg) Fasted vs fed state Stomach, duodenum,
jejunum
Systemic circulation
(Koenigsknecht et al., 2017)
Abbreviations: PPI, proton pump inhibitor; HP-β-CD, hydroxypropyl-β-cyclodextrin; TPGS, d-α-tocopheryl polyethyleneglycol 1000 succinate.
a Unless otherwise stated, drugs were orally administered to fasted healthy volunteers with a standardized amount of water (180–330mL). Fed state conditions
resulted from intake of a liquid meal prior to drug administration.
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volunteers (Fig. 4) (Brouwers et al., 2017). Using double-lumen tubes,
positioned with the help of fluoroscopy, gastric and duodenal fluids
were aspirated at predetermined time intervals and analyzed for (i) the
total content of itraconazole (as solute and solid), (ii) itraconazole in
solution, and (iii) the solubilizing capacity of the fluids for itraconazole.
The obtained concentration-time profiles demonstrated that both for-
mulations generated intraluminal itraconazole concentrations that
substantially exceeded the solubilizing capacity of the fluids (i.e., su-
persaturation), thereby enabling absorption. Compared to the solid
dispersion, intake of the cyclodextrin-based solution resulted in a much
higher dissolved fraction of itraconazole in the duodenum, explaining
the improved absorption seen in the simultaneously assessed systemic
concentration-time profiles (Fig. 4).
The gastrointestinal concentration-time profiles of poorly water-
soluble drugs in humans may act as excellent reference data to optimize
in vitro and in silico simulation tools. For instance, data on the intestinal
precipitation of posaconazole in humans have been used to validate a
physiologically based pharmacokinetic model for drug dissolution, su-
persaturation and precipitation (Hens et al., 2017b). Also, the value of
the Biorelevant Gastrointestinal Transfer (BioGIT) system to predict the
dissolved fraction of posaconazole and itraconazole in the upper small
intestine has been confirmed by comparison with intestinal con-
centration-time profiles obtained in humans (Kourentas et al., 2016b).
The simultaneous assessment of gastrointestinal and systemic con-
centrations further helps to identify the factors and processes critical for
absorption. For instance, intestinal concentrations of itraconazole after
intake of the above-mentioned cyclodextrin-based solution were sub-
stantially reduced by the intake of additional water (Berben et al.,
2017). However, the systemic exposure to itraconazole was not affected
by water intake. Without water intake, the cyclodextrins present in the
formulation were less diluted and stronger higher-order inclusion
complexes were formed with itraconazole in the small intestine,
thereby reducing precipitation and increasing concentrations. How-
ever, these stronger complexes also reduced the apparent permeability
of the intestinal mucosa for itraconazole (entrapment), as was demon-
strated by determining the permeation of itraconazole from the aspi-
rated fluids across Caco-2 monolayers. This illustration of the interplay
between solubility and permeability in the human gastrointestinal tract
stresses the need to implement permeation testing into formulation
evaluation when working with solubilizing approaches. As such, these
observations stimulated the further development of cell-free permea-
tion tools than can be easily implemented into traditional dissolution
testing (Berben et al., 2018a; Berben et al., 2018b).
Overall, the profiling of drug concentrations in the upper gastro-
intestinal tract provides a unique insight into the processes underlying
intestinal drug absorption. The added value of this approach for drug
development primarily lies in guiding the physiologically-based opti-
mization of in vitro and in silico simulation tools. To this end, it is critical
to link the observed intraluminal drug behavior to important gastro-
intestinal variables. Using the aspiration approach, these variables are
limited to the composition of the fluids (pH, bile salts, phospholipids,
food (digestion) products). Therefore, advanced approaches are being
explored to monitor additional gastrointestinal variables in parallel. In
this respect, recent advances in combining fluid aspiration with
manometry to monitor gastrointestinal motility (Bermejo et al., 2018;
van den Abeele et al., 2017a) offer new opportunities to fully elucidate
the interaction between drug products and the gastrointestinal en-
vironment.
For obvious ethical reasons, gastrointestinal aspiration studies can
only be performed in healthy adults, and not in specific patient popu-
lations including pediatric and geriatric patients. Making the in vitro
and in silico simulation of gastrointestinal drug behavior also relevant
for special populations is currently a major challenge. To this end, it is
essential to use patient data to characterize the gastrointestinal phy-
siology in these populations, as has been done recently with respect to
gastric fluid composition in neonates, infants and children (van den
Abeele et al., 2018). Based on such data, the sensitivity of the drug
product behavior to relevant population-dependent deviations in gas-
trointestinal physiology can then be evaluated in simulation tools.
5.2. In vitro digestion evaluation
Ingestion of lipids induces a two-way interaction between the for-
mulation and the GI tract. On one hand, lipids are digested by various
Fig. 4. Illustration of the gastrointestinal aspiration approach to study the intraluminal behavior and systemic absorption of itraconazole upon intake of a solid
dispersion (Sporanox® capsules) or a cyclodextrin-based solution (Sporanox® solution). Left panel: mean concentration-time profiles of itraconazole in the human
intestine (solid lines: itraconazole in solution, grey area: total itraconazole, red dotted line: itraconazole solubility). Right panel: mean concentration-time profiles of
itraconazole in the systemic circulation. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Data from Brouwers et al. (2018).
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lipases secreted by the stomach and the pancreas to transform lipophilic
compounds into more hydrophilic ones (N'Goma et al., 2012). The
modification of the chemical composition of the lipids – even lipid-
based surfactants that are esters of synthetic polymers such as poly-
ethylene-glycols can be digested (Fernandez et al., 2007; Fernandez
et al., 2008) - also affects their colloidal structures and favors the for-
mation of mixed vesicles, lamellar phases and micelles (Chamieh et al.,
2017; Fernandez et al., 2013; Müllertz et al., 2015; Vithani et al., 2017;
Vithani et al., 2019). On the other hand, the presence of lipids will
modify the gastrointestinal physiology by slowing down the gastric
emptying, stimulating the synthesis and secretion of bile, and the se-
cretion of pancreatic juice. All these events can affect the intraluminal
performance of LBFs and their ability to solubilize the drugs in colloidal
structures (Feeney et al., 2016).
To better anticipate the effect of lipolysis on the performance of
lipid containing drug delivery systems, a digestion test has been pro-
posed using a pH-stat apparatus. This device has been used by the food
and biochemical fields for decades and was transposed to the phar-
maceutical field in the last two decades. Lipids or LBF can be dispersed
in a lipolysis medium mimicking the gastric or intraluminal content
with lipases to start the lipolysis of ester-based compounds. The release
of fatty acids by lipases can decrease the pH of the medium depending
on their pKa and the pH-stat apparatus allows maintaining the pH
constant by addition of sodium hydroxide with an automated burette
(Bakala-N'Goma et al., 2015). Various lipolysis media compositions and
operating conditions have been described in the literature to either
mimic the fasted (Sassene et al., 2010) or fed (Fernandez et al., 2009)
state human GI conditions. An international LFCS consortium proposed
a standardized and validated test using the pH-stat apparatus to study
the lipolysis of LBFs in the small intestine (Williams et al., 2012b). They
described the composition of the lipolysis medium to mimic the fasted
duodenal conditions in term of calcium and pancreatin (lipases) con-
centration (Sassene et al., 2014), as well as the type and concentration
of bile salts (Williams et al., 2012a). Another harmonized test has been
proposed by the COST action INFOGEST for the food industry with a
three steps lipolysis protocol – oral (mouth), gastric and intestinal phase
(Minekus et al., 2014). This static in vitro simulation of gastrointestinal
food digestion has been recently amended and improved by the inclu-
sion of gastric lipase during the gastric step (Brodkorb et al., 2019).
Indeed, this improvement has been made possible by the recent com-
mercial availability of gastric lipase in rabbit gastric extract (since
2018) and the validation of the utility of this extract to mimic the
human gastric digestion phase of both lipids and proteins (Capolino
et al., 2011; Sams et al., 2018). An update of the LFCS protocol for the
evaluation of LBFs has not yet been proposed. However, the behavior of
LBFs in fed conditions is highly relevant as the increased pH in the
stomach will favor the action of the gastric lipase and preduodenal
digestion of the formulation with potential precipitation of the drug.
This would lead to a decreased amount of solubilized drug reaching the
small intestine and could preclude its absorption.
The lipolysis test is mainly currently used to evaluate the ability of
the LBF to transfer the drug in solution from the dispersed LBF toward
the formed colloidal phases and finally micellar solubilization (Feeney
et al., 2016; Mu et al., 2013). The drug can either be dissolved in mi-
celles, in supersaturation in the aqueous phase or precipitate in its
crystalline or amorphous form. Various techniques have been used to
follow the evolution of the colloidal phases – cryogenic transmission
electron microscopy (cryo-TEM) (Tran et al., 2017b), in situ synchrotron
small-angle X-ray scattering (SAXS) (Tran et al., 2017b; Vithani et al.,
2017), dynamic light scattering (DLS) or Taylor dispersion analysis
(TDA) (Chamieh et al., 2017) - and the fate of the drug - chromato-
graphic assay (Jannin et al., 2015), Raman spectroscopy (Stillhart et al.,
2013), and cross polarized optical microscopy (Williams et al., 2013).
Depending on the amount of drug in colloidal solution after 1 h of li-
polysis, the performance of the formulation can be classified toward its
precipitation propensity (Williams et al., 2014b). It is assumed that the
drug solubilized in the colloidal phases will be more readily available
for absorption and thereby favor in vivo drug exposure, while the pre-
cipitated drug will not be able to dissolve in the luminal content and
will not be available for absorption. This is not the case for some drugs
that are precipitating in the amorphous form from long chain LBFs like
cinnarizine (Sassene et al., 2015) and thus easily re-dissolve in the li-
polysis medium (Sassene et al., 2010).
Following that consideration, some in vitro-in vivo correlation stu-
dies have been conducted and led to ambiguous results with good rank
order correlation for danazol (Cuiné et al., 2007) or griseofulvin (Dahan
and Hoffman, 2007), and no correlation for fenofibrate (Griffin et al.,
2014; Tran et al., 2017a). One explanation of the lack of correlation is
the missing absorption step in the existing in vitro lipolysis models, this
is especially important for readily absorbed drugs, for which the di-
gestion of the excipients, and subsequent drug solubilization in the
digested media, are of minor importance (Griffin et al., 2014; Larsen
et al., 2013). Another issue is the species-specific consideration, e.g.
application of an in vitro lipolysis model that simulate human intestinal
conditions to compare with a pharmaco-kinetic study carried out in a
preclinical species, e.g. the rats (Anby et al., 2014, Siqueira et al., 2017).
Based on these observations, Jørgensen et al. (2018) developed an in
vitro lipolysis model, simulating the rat GI tract. The model also in-
cluded a gastric emptying step and was shown to better correlate with
the in vivo pharmacokinetic profile. The simulation of the performance
of LBF, could also be significantly improved if the data could be in-
corporated into PBPK models, however, this, however, is not yet pos-
sible.
To conclude this section, the current two main limitations of the in
vitro lipolysis test are the absence of gastric digestion phase and the lack
of drug absorption from the lipolysis vessel to better anticipate drug
partitioning. The first limitation should be solved in the near future as
gastric lipase is now commercially available (e.g. rabbit gastric extract).
Solutions to the latter limitation will be discussed in the following
chapter as promising results were obtained by Bergström and coworkers
very recently (Keemink and Bergström, 2018; Keemink et al., 2019).
5.3. Coupling techniques: dissolution/permeation
Common in vitro approaches to predict the biopharmaceutical per-
formance of enabling formulations measure drug solubility- or dis-
solution rate - improvement with regard to “apparent” solubility. For a
more detailed discussion of the terms apparent and molecular solubility
see Section 5.4. There is growing evidence, however, that the rate and
extent of drug absorption does not always correlate well with the
concentration of apparently dissolved drug. Since oral absorption is a
process in which dissolution and permeation occur concurrently and
sequentially across intestinal barrier, in vitro models that combine dis-
solution/permeation (D/P) are considered promising to mimic the in
vivo absorption process. The D/P approach was first introduced by
Ginski and Polli (Ginski, 1999), and since then many variants have been
developed at different levels of complexity to meet specific objectives,
such as estimating the effect of pH change (Liu et al., 2013), food intake
(Kataoka et al., 2011), and the dosage form (Motz et al., 2007) on the
oral absorption of drugs. While common permeation screens (Caco-2,
PAMPA, PVPA) in general demonstrated good in vitro-in vivo correla-
tions when testing pure drug compounds, up to now there is only
limited experience with the application of D/P-models for enabling
formulations (Kataoka et al., 2006). Several obstacles seem to have
hampered a faster development. The standard cell-based permeation
models, such as e.g. Caco-2 cell monolayers, have some limitations for
formulation screening. They typically cannot resist the solubilizing
additives in e.g. LBFs (Bibi et al., 2015), however, a recently developed
dynamic digestion-permeation assay making use of immobilized en-
zymes for digestion has proven compatible with a range of such for-
mulations (Keemink and Bergström, 2018; Keemink et al., 2019). Other
drawbacks are that they require long cell incubation times (21 days),
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and that the poor inter-laboratory comparability make it difficult to
compare results produced in different laboratories (Hayeshi et al.,
2008). Non-cellular barriers, such as parallel artificial membrane per-
meability assay (PAMPA) and phospholipid vesicle-based permeation
assay (PVPA) (Flaten et al., 2006b), are promising alternatives for as-
sessing passive, transcellular permeability and have recently been em-
ployed in D/P setups (Berben et al., 2018a; Gantzsch et al., 2014;
Kataoka et al., 2014). Although contradicting and alternative findings
have been reported, PAMPA and PVPA appear to have the inherent risk
of lacking functional stability against numerous solubilizing excipients
typically used in enabling formulations as well as biomimetic media.
Furthermore, PAMPA lacks biomembrane-like structures, making it less
bio-mimetic and for PVPA a laborious preparation procedure needs to
be adopted to overcome limited functional stability and short shelf-life
(Flaten et al., 2006a).
In 2016, Di Cagno and Bauer-Brandl proposed a new biomimetic
barrier, Permeapad® (Di Cagno and Bauer-Brandl, 2016), for a fast and
reliable determination of drug passive permeation properties (Di Cagno
et al., 2015). Recent pilot studies, employing the Permeapad® within
the commonly used side-by-side diffusion chamber, indicate a great
potential to specifically assess enabling formulations D/P-performance,
since the barrier is compatible with a wide range of surfactants, co-
solvents, and biomimetic media and even withstands lipolysis condi-
tions used for SEDDS and SNEDDS (Bibi et al., 2017; Flaten et al.,
2006a). At the same time, these studies revealed a limitation of the
conventional side-by-side diffusion chamber geometry in terms of per-
meation surface area. It has been postulated that a significantly dif-
ferent design, with a larger barrier interface, is needed, assuming that a
larger barrier interface to volume ratio will enable to study the mutual
interplay of dissolution rate with corresponding barrier flux under non-
steady state conditions, where dissolution is rate limiting as it is the
case in vivo (Sironi et al., 2017a; Sironi et al., 2018). During the past
two years, several groups have suggested a range of alternative ex-
perimental set-ups for combined dissolution/permeation testing; these
are summarized in the table with regard to the type of barrier used and
setup-geometry, i.e. donor volume, effective barrier area, and area/
volume-ratio (Table 6).
Depending on geometry and permeability of the drug compound
across the chosen barrier, different scenarios of interplay between ab-
sorptive flux (or mass transfer) and dissolution (or release) can be ex-
pected: For very low A/V-ratios (0.1 and below) the fraction of drug
removed from the dissolution chamber during the entire duration of the
D/P-experiment typically is negligible. Still, such approaches are
deemed useful because they may report the “fraction of permeable
drug”, which often is different from the fraction of (apparently) dis-
solved drug. For high A/V-ratios (1 and above), a significant feed-back
of absorptive flux (mass transfer) on drug dissolution and/or super-
saturation has been documented (Sironi et al., 2017a; Hate et al., 2019),
although the fraction of absorbed (transferred) drug still mostly is low
in comparison to that observed in vivo. A substantially higher super-
saturation has been observed in the presence of an absorptive com-
partment (than in the absence) for a fenofibrate nanoformulation
(Sironi et al., 2017b), despite the fact that the A/V-ratio in the side-by-
side setup employed was moderate (0.35).
5.4. Differentiation between apparently dissolved drug and molecularly
dissolved drug
In order to rank enabling formulations by biopharmaceutical per-
formance prediction from in vitro experiments, typically drug solubility
improvement is employed.
It is useful to differentiate between “molecularly” dissolved and
“apparently” dissolved drug molecules. “Molecularly” dissolved solutes
are “free”, i.e. individual molecules surrounded by their hydration
shells (Frank et al., 2012a). The term “apparently dissolved” includes -
in addition to the molecularly dissolved fraction - the solubilizedTa
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fraction of drug molecules that are present in various colloidally asso-
ciated or complexed states (Augustijns et al., 2014; Buckley et al.,
2013). Relevant colloids in this context are micelles, mixed micelles,
and vesicles formed by formulation additives or those present in human
or artificial (biomimetic) dissolution media (Elvang et al., 2016; Elvang
et al., 2018). Free drug molecules and those associated with colloids
behave differently in both thermodynamic (solubility) and kinetic
(dissolution rate; permeation) settings. This is of particular significance
with respect to bioavailability of enabling formulations permeation
(absorption). It has been hypothesized that the “molecularly” dissolved
drug molecules, but not the colloidal drug associates, permeate across
biological barriers; the “apparently” dissolved drug fraction appears not
to correlate well with permeability (Buckley et al., 2013; Fong et al.,
2017a). This means in other words that absorption/permeation rates
would essentially depend on the molecularly dissolved drug con-
centration. During the time course of a dissolution experiment for oral
drug delivery systems, the free drug concentration depends on mole-
cular solubility, and the kinetics of distribution of molecules in and out
of the respective colloidal adducts and other particles (Fig. 5).
Molecular drug concentration would thus probably be a better
predictor of absorption and bioavailability than the apparently dis-
solved concentrations and apparent solubility (Frank et al., 2012a).
However, in literature, with few exceptions, apparently dissolved drug
concentrations are reported because they are experimentally readily
accessible by filtration or centrifugation, whereas assay of the mole-
cularly dissolved drug concentration is done by dialysis methods, where
it takes several hours/days to reach equilibrium.
However, in vivo oral drug delivery systems meet rapid dynamic
changes of environment during their GI transit - the time period of
which in total is 2–6 h, including pH jump, mechanical exposure, food
effects, digestion fluids etc. While the conditions in the GI fluids con-
tinuously change, drug molecules are exchanged between molecularly
dissolved, colloid-associated and particulate states. Simultaneously,
free drug molecules are absorbed and thus eliminated from the media.
Therefore, in many cases, when starting from a solid formulation, so-
lubility limits for the API (apparent solubility) are not reached in vivo,
making (apparent) solubility a weak tool to predict biological
performance.
An approach to circumvent the outlined difficulties is to develop in
vitro models mimicking the interdependent dynamics of dissolution and
elimination/permeation processes (see Section 5.3 on combined dis-
solution and permeation) possibly allow to follow supersaturation and
change in solubilization through media composition changes and si-
multaneously decreasing the free drug concentration by a permeation
(absorption) sink. In such experiment, changing compositions, rates of
transport etc., need to be in a realistic balance to mimic the dynamic
interrelationship between colloids, molecules, precipitates, and
permeates. If the chosen conditions are suitable, it is a pragmatic ap-
proach for screening and ranking of formulations to look at permeation
rates and quantities through biomimetic barriers, because such set-up
already implies the distinction and dynamic interrelationships between
molecular and apparent drug concentrations.
If, however, a better mechanistic understanding is desirable to make
rational decisions and to optimize formulations, on-line time-resolved
measurement of molecularly dissolved drug fraction evolving from a
drug delivery system in a dynamic model is needed. Recently, it has
been suggested to employ microdialysis to address this challenge (Fong
et al., 2017b). While microdialysis has already been established for in
vivo (animal) studies and clinical settings to measure drug exposure in
tissues, its use for in vitro dissolution and dissolution-/permeation
methods is in its infancy. Koplin et al. have refined the suggested ap-
proach and demonstrated the implication of colloidal solubilization on
in vitro extraction rates (Koplin et al., 2017).
There is currently very limited experience with D/P-systems com-
prising on-line assay of the molecularly dissolved drug concentrations.
First, D/P-systems in conjunction with microdialysis-sampling should
enter broader use and more data should become available from in vitro
screening of enabling formulations with established in vivo perfor-
mance. Then it may become possible to conclude if this approach helps
to find the optimum formulations faster and more reliably thereby
tremendously reducing the number of animal studies.
Fig. 5. Schematic representation of the impact of molecularly dissolved drug fraction and other states on bioavailability of oral drug delivery systems.
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5.5. Mucus diffusion
The mucus gel layer covering the GI epithelium represents a further
barrier for orally administered therapeutics and in particular for micro-
and nanocarrier systems that are supposed to overcome it. Generally,
the mucus barrier restricts drugs and drug delivery systems on their
way to the absorption membrane by its adhesive and viscous properties.
The adhesive properties of mucus are, on the one hand, related to (I) its
anionic character due to sialic- and sulfonic acid substructures ionically
binding cationic drugs and drug carriers (Crowther and Marriott, 1984),
(II) its hydrogen bonding properties due to oligosaccharide sub-
structures (Braybrooks et al., 1975) and (III) its partially lipophilic
character due to fatty acid substructures being responsible for hydro-
phobic interactions (Lichtenberger, 1995). The viscous properties, on
the other hand, are mainly based on mucus glycoproteins exhibiting
cysteine-rich subdomains that are connected with each other via dis-
ulphide bonds building up a stable three-dimensional network structure
with a mesh size in the range of 10–200 nm. The larger the diameter of
drugs or carrier systems, the more is their diffusion across the mucus gel
layer hindered (Desai et al., 1992; Griesser et al., 2018). To which ex-
tent the adhesive and to which extent the viscous properties of the
mucus barrier are responsible for the reduction in the diffusion rate,
however, is difficult to determine.
Methods that are useful to evaluate the mucus permeation behavior
of drugs and drug delivery systems in vitro include over all equilibrium
dialysis, rheological studies and mucus diffusion studies. Crucial for all
these techniques is the use of freshly isolated native mucus. Methods to
isolate mucus form porcine and bovine GI-tract have been described in
detail previously (Allen et al., 1989).
To evaluate the binding and interactions of drugs and carrier sys-
tems with mucus equilibrium dialysis and rheological studies are re-
commended. Most commonly, isolated mucus is loaded into dialysis
sacs and immersed in a buffer system containing the drug of interest.
Once equilibrium has been reached the extent of binding to the mucus
can be determined (Crowther and Marriott, 1984; Kearney and
Marriott, 1987). Alternatively, rheological synergism has been pro-
posed as an in vitro parameter to evaluate drug or drug delivery system
– mucus interactions: the higher the rheological synergism, the stronger
are these interactions (Marriott and Kellaway, 1975; Müller et al.,
2013).
In contrast to mucus equilibrium dialysis and rheological studies,
diffusion studies are more informative. In its simplest form, a cylind-
rical diffusion chamber is filled with mucus and on one end the drug or
nanocarrier system of interest is applied. After incubation of at least
several hours up to several days at 37 °C, the amount of drug or na-
nocarrier is quantified in pre-determined segments of the cylinder
(Larhed et al., 1997; Pereira de Sousa et al., 2015). Although the
method is comparatively simple, it has the disadvantage that at short
incubation times of just a few hours it is difficult to discriminate the
diffusion behavior of different nanocarriers. On contrary, long incuba-
tion times of several days are time consuming and a decrease in mucus
stability over time has to be taken into consideration. In Fig. 6 an ex-
ample of results obtained with this method is provided. Particles having
been decorated with different mucolytic proteases showed in this test a
mucus permeation behavior that correlated very well with in vivo re-
sults (Mahmood et al., 2017).
In contrast to permeation studies utilizing mucus sandwiched be-
tween filters facing the donor and acceptor compartments (Desai et al.,
1992; Friedl et al., 2013), the method is independent from parameters
that are difficult to control such as the thickness of the mucus and
unstirred water layer or membrane effects of the filter. Furthermore, via
this method even the self-diffusion coefficient of the diffusing species in
mucus can be determined rather than just the percentage of drug or
carrier system having permeated the mucus layer in a certain time
period in dependence on the applied concentration gradient. Further-
more, even the impact of water movement through the mucus, as it is
the case in the intestine because of extensive water absorption, can be
simulated (Fabiano et al., 2017). Microscopic techniques are also based
on mucus diffusion studies allowing a more rapid determination of the
diffusion coefficient (Henry et al., 1992). Via video microscopy fol-
lowed by post-acquisition analyses the diffusion coefficient even of
nanocarriers in mucus can be determined. As several particles can be
simultaneously tracked via this technique, it is also known as multiple-
particle-tracking (MPT) (Crocker and Grier, 1996). In order to visualize
nanocarriers in the mucus they have to be labeled on their surface
preferably by fluorescence dyes. Apart from microscopic techniques the
diffusion of drugs and carrier systems in mucus can also be analyzed via
pulsed-gradient spin-echo NMR (PGSE-NMR) (Occhipinti and Griffiths,
2008). In contrast to microscopic techniques a fluorescence labelling of
the drug or of the carrier system, with all its drawbacks such as altering
the original properties of diffusing species because of the labelling or an
unintended release of the label causing misleading results, is not
needed. The likely only A drawback is that the sample must contain a
spin-active nucleus such as 1H or 19F. Furthermore, the method is
comparatively more complex than all other techniques depending on
high-tech equipment.
Fig. 6. A: Penetration capacity of fluorescein diacetate (FDA) labeled papain decorated microparticles (blue bars), bromelain decorated microparticles (red bars) and
undecorated microparticles (grey bars) analyzed via rotating silicon tube method at 37 °C for 4 h; B: Percentage of FDA incorporated in papain decorated micro-
particles (blue bars), bromelain decorated microparticles (red bars) and undecorated microparticles (grey bars) remaining on rat gastrointestinal mucosa within 3 h
after oral administration; adopted Mahmood et al., 2017. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version
of this article.)
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5.6. In vitro and ex vivo absorption evaluation: cell-based models and
Ussing chambers
Despite the presence of numerous in vitro models for evaluating
PWSDs behavior (see compendial and state-of-the-art methods de-
scribed in previous chapters), in vitro cell-based and ex vivo methods
provide a compromise between the complex and expensive in vivo
models and the simplicity and one-dimensional feature of in vitro
models. In vitro cell based models provide an intermediate complexity
and resemble the in vivo system more closely. Furthermore, they also
allow studying the interaction of these systems with human-originated
cells and tissues that include the transport systems in the human in-
testine. Furthermore, simple buffers can also be replaced with simu-
lated intestinal fluids for adding another component to the system
(Antoine et al., 2015).
Starting with the cell-based systems, the ability of Caco-2 based
systems to form polarized monolayer with transporters, tight junctions,
mucus layer (with HT29-MTX cells) and M-cells (with Raji B cells)
provide a wide array of models with which the advanced drug delivery
systems can be evaluated. In addition, these models can also be used to
evaluate the transport mechanism by using specific inhibitors. Also, for
ex vivo models, the possibility to use human intestinal tissue provides
more information on how the system would behave in the in vivo
conditions. Finally, the Ussing chambers system allows using different
segments of GI tract, giving information on how the drug and the de-
livery system interact with these specific segments.
Both systems, especially cell-based models, have been used ex-
tensively to evaluate different advanced drug delivery systems such as
polymeric nanoparticles, lipid nanoparticles, silica and silicon nano-
particles, nanocomplexes, etc. The ease of establishing the system and
performing the experiments allow us to easily evaluate advanced drug
delivery systems. Some examples of information that can be gathered
from these systems include: (i) absorption behavior and permeability,
(ii) interaction with the mucus layer, (iii) interaction with the cell
monolayer, (iv) mechanism of transport, (v) influence of membrane
transporters, and (vi) comparison of interaction with different segments
of the GI tract.
The following two sub-sections present both in vitro cell-based
methods and ex vivo Ussing chambers, summarizing their key attributes
and limitations.
5.6.1. In vitro cell-based models
In vitro cell-based studies offer a compromise between in vitro stu-
dies and in vivo studies, by providing intermediary level of complexity,
feasibility and some resemblance to the in vivo condition. Further, they
help in significant reduction in the usage of animals, while still pro-
viding information regarding the tested drug molecules. Especially, in
the case of monolayers in Transwell® systems which provide an esti-
mation of drug permeability across polarized intestinal cellular mono-
layer (Pereira et al., 2016).
In vitro cell culture methods are extensively used to evaluate in-
testinal permeability of drug molecules and/or interaction with the
drug delivery systems rapidly. These in vitro intestinal cell culture
models are developed primarily using immortalized cell lines as the use
of primary cell lines have been generally restricted owing to their in-
ability to form polarized epithelial monolayer in in vitro conditions
(Bohets et al., 2001). There are several types of immortalized cell lines
used for this purpose, such as the human colon adenocarcinoma (Caco-
2), mucus-producing goblet-like cells (HT29-MTX), Madin-Darby Ca-
nine Kidney (MDCK) cells and 2/4/A cells. These cell lines are used
either individually or in co-culture to form an in vitro intestinal model
ranging from simple two-dimensional cell monolayer to three-dimen-
sional model compromising of three or more cell lines. A summary of
the different cell-based models reviewed in this section are described in
Table 7.
Caco-2 cells are considered as the ‘gold standard’ and have been
extensively used for gathering vast information regarding in vitro drug
absorption. Caco-2 cells seeded in Transwell® membrane filters differ-
entiate into mature polarized enterocytes, with brush bordered apical
side and basolateral side after 19–21 days. Caco-2 monolayers also
present the tight junctions between the cells and express several
membrane transporters that are present in intestinal epithelia. In vitro
Caco-2 cell-based monolayers has been used to evaluate intestinal
permeability of both small molecule drugs (Mäkilä et al., 2016; Zhang
et al., 2012) and large biopharmaceuticals (Li et al., 2014; Shrestha
et al., 2018). However, monoculture Caco-2 monolayer models are far
from perfect as they lack several important features of intestinal epi-
thelia such as presence of mucus-layer, barrier properties similar to
colonic epithelia, poor expression of intestinal enzymes (e.g. CYP3A),
high variability among clones, and absence of other cell types such as M
cells and fibroblasts (Sarmento et al., 2012). To overcome these
Table 7
Characteristics of different intestinal cell models used for assessing the intestinal absorption.
Cell line Source Characteristics References
Caco-2 Human colorectal
carcinoma
Differentiation into mature enterocytes with apical and basolateral side;
Production of tight junctions; Expression of a wide range of transporters
(Artursson et al., 2001; Buckley et al.,
2012; Sarmento et al., 2012)
TC-7 Human, Clone of Caco-2 Morphologically similar to Caco-2; Higher homogeneity and lower variability
than Caco-2; High enzyme content and lower P-gp expression; Suitable for
passively transported molecules only
(Buckley et al., 2012; Turco et al., 2011)
2/4/A1 Rat Lower number of active drug transporters and looser tight junctions; ‘small
intestine-like’; Suitable for passively/paracellularly transported drug molecules
(Tavelin et al., 2003)
MDCK Canine, dog kidney cell line Non-intestine and non-human derived cell lines; Comparable to Caco-2 models
for drugs using passive transcellular pathways; Low expression of drug
transporters
(Bohets et al., 2001; Irvine et al., 1999)
HT29/MTX Human colorectal
carcinoma
Goblet cells; Mucus producing cells (Araújo and Sarmento, 2013; Lechanteur
et al., 2018; Sarmento et al., 2012)
Raji B Human, B-lymphocytes Used for conversion of enterocytes to M cells; Used in co-culture with enterocyte
like cells.
(Beloqui et al., 2017; Des Rieux et al.,
2006)
Caco-2/HT29-MTX Human colorectal
carcinoma
Produces co-culture monolayer with absorptive enterocytes and goblet cells that
produces mucus covering the monolayer; Barrier properties can be controlled
based on the day of seeding HT29-MTX cells
(Béduneau et al., 2014; Mahler et al.,
2009; Wikman-Larhed and Artursson,
1995)
Caco-2/Raji B (FAE) Human colorectal
carcinoma/B-lymphocytes
Resembles human follicle-associated epithelium; Co-culture produces Caco-2
cells with interspersed M-cells; Useful for uptake and internalization studies
(Beloqui et al., 2017; Des Rieux et al.,
2006)
Caco-2/HT29-MTX-
Raji B
Human colorectal
carcinoma/B-lymphocytes
Closely resembles the human intestinal epithelia, with monolayer comprising of
three major cells, enterocytes, mucus-producing cell line and M cells; Barrier
properties closely resembling small intestine
(Antunes et al., 2013; Araújo and
Sarmento, 2013)
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limitations, several strategies have been evaluated such as use of sub
clones of Caco-2, use of co-culture technique and alternative cell lines.
Owing to the heterogeneity of Caco-2 cell lines, sub clonal cell lines
such as TC-7 have been isolated, which have shown to improve
homogeneity, and also demonstrate higher enzyme content and lower
levels of P-glycoprotein (P-gp) (Pereira-Caro et al., 2010). However,
Turco and co-workers have demonstrated that TC-7 cell-based models
are suitable only for passively diffusing molecules. On the other hand,
TC-7 cells have been regarded as unsuitable for lipophilic and poorly
absorbed drugs, and when active transport and/or first pass metabolism
is involved (Buckley et al., 2012; Turco et al., 2011). Another alter-
native cell line used for intestinal permeability is the rat-derived 2/4/
A1 cell line. This cell line has lower number of active drug transporters
and has looser tight junctions similar which are more similar small
intestine compared to colon-like tight junctions in Caco-2 cell lines,
thus making it a more promising alternative to Caco-2 monolayer for
passively transported drug molecules (Artursson et al., 2001; Tavelin
et al., 2003). MDCK cell lines is another alternative, which are derived
from dog kidney cells. Despite its non-human origin, these cells are
comparable to Caco-2 models for drugs using passive transcellular
pathways and exhibit low expression of drug transporters and have
negligible metabolic activity (Buckley et al., 2012; Irvine et al., 1999).
In addition to these simple monoculture models, advanced co-cul-
ture and triple co-culture models have been developed to incorporate
the other important features of intestinal epithelium. Since its estab-
lishment in 1995, co-culture of Caco-2 and HT29-MTX has been used
significantly. The major characteristics of this model is the presence of
mucus layer and reduced TEER values which are more comparable to
small intestine values (Araújo and Sarmento, 2013; Mahler et al.,
2009). The co-culture model allows evaluation of influence of presence
of mucus in drug transport and absorption. Moreover, another study has
also demonstrated the influence of the day of the seeding of goblet cells
on the barrier properties which includes P-gp expression and para-
cellular transport (Béduneau et al., 2014).
A co-culture model using Caco-2 and lymphocyte Raji B cells that
mimic human follicle associate epithelium (FAE) have also been stu-
died. In the presence of Raji B cells, the enterocytes are converted into
M cells, which are a part of mucosal immune system and are mainly
found in the FAE of Peyer's patches. M cells are responsible for trans-
cytosic pathway and has the capability to transport wide array of
cargos, from drug molecule to therapeutic nanosystems. The successful
development of this co-culture is determined by reduced TEER values,
increased translocation, loss of microvilli and increased bacterial ad-
herence and translocation (Beloqui et al., 2017; Des Rieux et al., 2006).
To achieve intestinal models that resemble the complexity and
closely mimic the in vivo condition, a triple cell co-culture model with
Caco-2/HT29-MTX/RajiB cells has also been developed. This model
combines the advantages of both the abovementioned two co-culture
models (Caco-2/HT29-MTX and Caco-2/RajiB) with the presence of
mucus layer, decrease TEER levels, and presence of M cells, all of which
closely resembles the intestinal epithelia (Antunes et al., 2013; Araújo
and Sarmento, 2013). Overall, this system would be a reliable in vitro
intestinal barrier model to study the absorption of drug molecules alone
or encapsulated in drug delivery systems (Sarmento et al., 2012).
5.6.2. Ex vivo technique: Ussing chambers
Despite wide application of in vitro cellular models, their use is
greatly limited by their inability to reflect the complexity and simulate
multiple conditions that exists in human intestine. In comparison, the
use of functional fresh tissues in ex vivo models demonstrate higher
degree of interplay among different cell types and closer resemblance of
in vivo conditions. Some of the extensively used ex vivo models used are
Ussing chambers, Franz cells, everted intestinal sac method, etc. (Pearce
et al., 2018; Nunes et al., 2016; Roeselers et al., 2013). In this section,
we will mainly discuss the Ussing chambers system as ex vivo model to
study physiology and permeability across intestinal epithelia.
Since its first use in 1950s by Hans Henriksen Ussing, the Ussing
chambers model has been used widely for studying physiology, trans-
port of molecules and nanoparticles in a wide variety of epithelial tis-
sues (such as intestine, retinal, reproductive tract, and exocrine/endo-
crine ducts) and cultured cell lines (Pearce et al., 2018; Kalman and
Ussing, 1955; Lundquist and Artursson, 2016; Clarke, 2009). Compared
to the original model, several modifications have been made to enhance
the performance of the model and numerous alternatives are available
(Nunes et al., 2016; Clarke, 2009). One of the major applications of
Ussing chambers has been in the field of intestinal physiology and
transport, in either rodent tissue or human tissue (Nunes et al., 2016;
Lundquist and Artursson, 2016; Clarke, 2009; Westerhout et al., 2014).
The use of human intestinal tissues in Ussing chambers experiments
have been significantly augmented owing to the increase in the number
of bariatric surgeries during which intestine tissue samples can be do-
nated without any safety problems to the patient (Ng et al., 2014).
Nonetheless, the tissues obtained from patients who are obese or suf-
fering from colorectal cancer differ from normal donors, and further the
tissue transport has to be fast to minimize tissue deterioration
(Lundquist and Artursson, 2016).
A schematic representation of the Ussing chambers is shown in
Fig. 7 (Westerhout et al., 2015). The Ussing chambers system mainly
comprises of chambers that are filled with nutrient rich buffer (com-
monly, Krebs Ringer buffer), and with a freshly excised and flattened
tissue that is positioned in the window between the two adjacent
chambers. The tissue is placed as such the mucosal side is facing one
chamber (referred as luminal side or apical), and the serosal side is
facing the second chamber (also known as basolateral side). The test
samples or formulations are placed on the apical side of the system
(Nunes et al., 2016; Lundquist and Artursson, 2016). Oxygen and
carbon dioxide (Carbogen gas for mammalian physiological buffers) are
continuously supplied to the system, which has additional benefit of
maintain the physiological pH 7.4 and maintaining minimum level of
unstirred layer. Both chambers are water-jacketed to maintain the
temperature at 37 °C (Clarke, 2009; Buckley et al., 2012). The chambers
can be either vertical or horizontal, and the electrophysiological
properties of the tissue are continuously monitored (Clarke, 2009).
Based on the time-concentration data obtained during the experiment,
apparent permeability of the drug can be estimated (Sjöberg et al.,
2013). In addition to commonly used buffers, several studies have de-
monstrated the possibility of using simulated fluids to more closely
resemble the in vivo conditions (Wuyts et al., 2015). Nonetheless the
intestinal integrity and viability must be continuously monitored and
can be measured by two electrodes in the two chambers, that measures
the TEER, potential difference and the short-circuit current (Sjöberg
et al., 2013; Lautenschläger et al., 2013). Additionally, markers such as
Lucifer yellow, lactate dehydrogenase release, and histological ex-
aminations can also be performed to ensure the viability of the tissue
(Nunes et al., 2016; Westerhout et al., 2015; Rozehnal et al., 2012).
Ussing chambers have been extensively used to study the perme-
ability of drug molecules in free form or encapsulated in nanosystems,
Fig. 7. Schematic representation of Ussing chambers model (Westerhout et al.,
2015).
B.J. Boyd, et al. European Journal of Pharmaceutical Sciences 137 (2019) 104967
19
across animal or human intestinal tissues (Sjöberg et al., 2013;
Rozehnal et al., 2012). This model can serve as a critical tool for
evaluating the interaction of nanoparticles with the intestinal epithelial
tissue in a more complex scenario as compared to cell-based models
(Lautenschläger et al., 2013). Several studies have used Ussing cham-
bers model to evaluate and understand the behavior of small molecule
drugs encapsulated in delivery systems. A recent study involved the
evaluation of carbamazepine permeability from lipid-polymer hybrid
nanoparticles in mice jejunal sections in Ussing chambers model (Ana
et al., 2019). Another study by Barbieri et al. (2015) evaluated the
permeability of anti-cancer drug tamoxifen from lecithin-chitosan na-
noparticles. Freshly excised rat jejunal tissues in Ussing chambers were
used to demonstrate the permeation enhancing effect of the nano-
particles as compared to the free drug suspension (Barbieri et al., 2015).
Overall, these studies demonstrate Ussing chambers model as a feasible
model to assess the permeability of drugs from advanced drug delivery
systems.
Ussing chambers system allows the measurement of intestinal
physiology and transport across intact polarized intestinal tissue for a
limited period and involves more complexity of the barrier when
compared to cell-based culture models. The model also allows bidir-
ectional drug transport and as well as the evaluation of the influence of
regional intestinal differences and species differences in drug transport
mechanism. Moreover, the influence of drug transporters expressed on
the intestinal tissues can also be assessed using this model (Nunes et al.,
2016; Clarke, 2009; Sjöberg et al., 2013; Fortuna et al., 2012). Despite
such advantages, Ussing chambers model is a labor-intensive process
and do not entirely mimic the in vivo situation, as it does not include
circulation and lymphatic drainage systems thereby limiting its appli-
cation to< 150–180min (Lundquist and Artursson, 2016; Westerhout
et al., 2015; Sjöberg et al., 2013). Furthermore, during the experiment
period the viability and the integrity of the tissue must be maintained.
Additionally, the overall process is time-consuming and there could be
possible damage or morphological changes during the tissue prepara-
tion, mounting or removal (Nunes et al., 2016).
6. Unmet technological needs and future prospects
6.1. Limitations of the available formulation-related technologies
Limitations from a technological viewpoint can be identified re-
garding formulation design as well as analytical technologies. It makes
sense to further consider limitations of silico tools and any other in-
formation technology that could guide formulation development.
Cheminformatics has in the drug discovery phase much contributed to a
better integration of otherwise fragmented information gathered across
the relevant disciplines (Lawless et al., 2016). Especially machine
learning and artificial intelligence are increasingly used in cheminfor-
matics to guide the selection of suitable drug candidates (Lo et al.,
2018). Compared to such approaches to obtain a viable drug candidate,
the development of the drug product is still guided mostly by expert
knowledge. Flow charts are given in the pharmaceutical literature to
aid with the selection of a suitable formulation approach for a new
active compound by addressing the individual physicochemical and
biopharmaceutical characteristics (Kuentz et al., 2016). However, with
an increasing flood of information coming from different computational
simulations (Section 3), in vitro methods (Section 4) as well as in vivo
experiments, it becomes difficult to keep up with informed decision
making about formulation and process technique. Formulation devel-
opment is therefore encouraged to increasingly use modern algorithmic
tools and there is much to learn from the drug discovery phase (Smith
et al., 2018). Just one example is whether or not multitask deep
learning is practical in pharma applications (Ramsundar et al., 2017).
Since evaluation of such algorithms requires rather large datasets, a
testing in drug discovery is so far much easier than in drug product
development. Further hurdles are in the present case both software
difficulties and lack of understanding of how robust such multitask
deep learning networks are. A possible solution is to provide high
quality open source software programs that can be used broadly in the
pharmaceutical industry (Ramsundar et al., 2017). Thus, what is cur-
rently missing is evaluation studies of such modern computational ap-
proaches in the field of drug product designs as well as manufacturing.
Another gap regarding formulation development is to have a
broader range of pharmaceutical materials and excipients to select
from. Many new concepts emerge from modern drug delivery and tar-
geting but they are hard to implement later in formulation development
based on the existing range of pharmaceutical additives (Tibbitt et al.,
2016). However, innovative excipients that are novel chemical entities
would have to overcome diverse toxicological as well as regulatory
hurdles in pharmaceutical development (Elder et al., 2016). Therefore,
much excipient novelty has been based rather on simple co-processing
of known excipients to enhance processability in manufacturing such as
to enhance tableting performance (Rojas et al., 2012). An interesting
idea is to harness molecularly designed interactions between additives
and polymers to obtain, for example, novel matrices for solid drug
dispersions, which demonstrate distinct advantages over a simple
physical mixture of the components (Ditzinger et al., 2019). The topic
of novel materials/excipients has to be addressed more extensively in
pharmaceutics to bring good novel drug delivery ideas to a formulation
technology that is viable on the market. The given technical possibi-
lities of novel materials/excipients have to be aligned with the needs
identified from oral delivery challenges. Such biopharmaceutical re-
quirements must be clarified based on proper understanding of how
formulations are intraluminally processed. The state-of-the-art methods
that were outlined in Section 5 therefore provide critical information on
what is needed from an oral delivery perspective. This should lead to
targeted characteristics of any novel excipients and their technical and
regulatory hurdles must be addressed to bring novel drug delivery ideas
to a viable formulation technology that can be introduced to the
pharmaceutical market.
Unmet technological needs are not only about market formulations
but are also given considering preclinical and clinical delivery systems
that are essential to develop drug products. There are, for example,
limitations in process technologies to obtain desired colloidal drug
delivery systems. Such colloidal solutions are mostly used as preclinical
or clinical oral formulations, but they also serve as intermediate pro-
ducts to obtain a final solid dosage form. Much innovation is expected
from microfluidic devices as they can handle liquids at the nanoliter
scale with advantages of process intensification (Mitic and Gernaey,
2016) and facilitated scale-up by multiplying the microscale circuits to
the needs of production. Microfluidics has been applied to prepare li-
posomes, lipid nanoparticles, polymeric nanoparticles, and other hybrid
nanoparticles (Garg et al., 2016).
Diverse limitations of formulation design and logistics may be ad-
dressed by another emerging technology that is about 3D printing of
drug products. This umbrella term actually includes different manu-
facturing techniques, which have basic elements in common. Thus,
material is deposited in digital controlled manner to produce a layer-by-
layer structure that can take any geometry of choice. This solid freedom
fabrication has been classified into printing based on inkjet systems,
nozzle-based deposition systems, and laser-based writing systems
(Goole and Amighi, 2016). To date, technologies based on 3D printing
techniques have been implemented for clinical use of printed medical
products such as implants and there is currently much emphasis on
printing drug products (Awad et al., 2018). Spurred by the first FDA
approval of a pharmaceutical product (SPRITAM®), the 3D printing
technology has gained momentum in pharmaceutics (Khatri et al.,
2018). There are obvious advantages of this approach to cope with
needs of increased product complexity, personalization, and on-demand
manufacturing (Norman et al., 2017). However, is it really a disruptive
innovation for pharmaceutical manufacturing in general or will it ra-
ther take in the future only niche applications in personalized drug
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products? Fig. 8 displays stake holders as well as key issues of 3D
printing that have to be addressed in the following years (Liang et al.,
2019). There is in particular a regulatory framework needed and as-
pects of quality control must be clarified when a community pharmacy
is printing drug products as personalized medicine. Since printing in a
pharmacy or a hospital is based on the contribution of the drug man-
ufacturer, software developer, and a pharmacist, it must be clarified
who is ultimately liable in case of any product failures. The true po-
tential of drug product 3D printing is therefore depending on how the
named key issues are addressed and solved over the coming years.
A further gap to overcome can be seen in the field of real-time
analytics. There is a broad range of process analytics and research into
novel dip probes or flow-through cells is ongoing (Simon et al., 2015).
Process analytical technologies have on the one hand relevance for
manufacture of pharmaceutical dosage forms (Rantanen and Khinast,
2015) but there is further usage that is of particular interest from a
biopharmaceutics perspective. Thus, real-time analytics is increasingly
used to obtain dynamic information from in vitro testing. Immersion
probes or flow-through cells are options to make use of, for example,
UV or vibrational spectroscopy, or by employing different sensors of
particle analysis (Kuentz, 2014). Analytical probes can hence aid with
closing the gaps addressed previously (in Section 5) on drug assessment
under biorelevant conditions and a prominent example is to use UV
immersion probes to assess drug supersaturation (Palmelund et al.,
2016). While UV dip probes are a relatively established technique, there
are novel process analyzers needed especially, when trying to cope with
complex media in simulated intestinal fluids. Formulation processing in
the intestine leads to dynamic changes of droplets, particles, and col-
loids emerging from pharmaceutical formulations. Apart from the
challenges to simulate these processes in vitro, it will be important to
also monitor changes in a dynamic way. Sensor probes should here not
only measure drug concentrations and optional supersaturation, but
also structural changes should be monitored and a challenging example
is digestion of LBF (Vithani et al., 2017; Kuentz, 2018). Such complex
media typically exhibit relatively high turbidity that makes it hard to
measure by means of any optical spectroscopy. Thus, especially
promising dip sensors for such complex digested formulations are po-
tentiometric probes that can measure free drug concentrations of io-
nizable compounds (Tran et al., 2018). Measurement free drug con-
centrations in real-time would be highly desirable in any in vitro test
because drug activity is driving the absorptive flux across the intestinal
wall. A finer monitoring of concentration changes by adequate real-
time analytics further help with a better understanding and ultimately
with computational modelling of how drug delivery systems are pro-
cessed in the GI tract.
In summary, the design of oral formulations should be based on data
from in silico, in vitro, and later in vivo data. Limitations are not just
given on the available types of materials, delivery systems, and man-
ufacturing techniques but also the limitations of computational and
analytical methods must be addressed in the context of oral formulation
design. Advancement of these formulation-related technologies will be
needed to address the still unmet needs of modern oral drug delivery.
6.2. Research strategies: a change of paradigm is needed
In prolongation of the above said, the assessment of drugs and de-
velopment of formulations regarding their probable biopharmaceutical
behavior the following strategies are proposed:
1) For the screening of new drug entities, a classical in vitro solubility
test and permeation test from solutions (both using artificial barriers
and cell-based assays) still appears suitable to classify the com-
pounds according to the expected kind and degree of problems in
their formulation and to choose a promising formulation strategy.
2) The use of biorelevant media to assess their interaction with the
main components of the fluids is also encouraged both for solubility
and for permeation.
3) However, for absorption (permeation) assessment and biopharma-
ceutical performance prediction of formulations, the concept of
freely dissolved drug molecules as being the key factor should be
appreciated. The consequent use of a clear nomenclature that dis-
tinguishes the apparently and molecularly dissolved fractions of the
Fig. 8. Stakeholders and key issues in the field of 3D printed drug products as modified from Liang et al. (2019).
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drug is needed.
4) Free drug concentrations evolving after dispersion of the respective
drug formulation in biorelevant set-ups, possibly including lipolysis
for LBFs, may be quantified by dialysis methods. However, a per-
meation experiment from such formulation dispersion may in a
pragmatic way include the concept of free drug concentration
within the permeation assay.
5) Such approach according to steps 1) to 3) still does not take into
account the dynamic changes occurring during the GI passage of
oral dosage forms, including dilution, changes of composition of the
digestive fluids, concentration changes due to absorption or meta-
bolism, etc. Combined dissolution/permeation approaches may
provide an experimental access to mimic such changes.
6) For detailed mechanistic studies, the investigation of the kinetics of
all the above named inter-related processes should take into ac-
count, including the active transport, metabolism etc. The models
will become increasingly complex according to increasing need for
better understanding and better modelling.
Therefore, for the time being, animal experiments are still needed to
validate the intraluminal behavior of drug from advanced drug delivery
systems.
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